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Abstract 
 
Melissa Whaley 
Role of Influenza among Adult Respiratory Hospitalizations: a Systematic Review 
(Under the direction of Dr. Lisa Casanova, faculty member) 
 
With the threat of avian influenza, influenza laboratory testing and surveillance capacity 
has increased globally. Data from global surveillance activities have been used to identify 
circulating influenza strains for vaccine policy decisions, and have provided evidence of 
influenza disease among various populations. A recent meta-analysis, which includes 
findings from these surveillance efforts, has shown that influenza contributes to 10% of 
pediatric respiratory hospitalizations. Although statistical models indicate a high burden 
of influenza-associated morbidity among older adults and pandemic studies reveal an 
increase in hospitalizations among young adults, the global burden of seasonal influenza 
among adults remains unknown. In order to estimate the global burden of seasonal 
influenza among adult respiratory hospitalizations, we conducted a systematic review of 
the published literature, and identified 48 eligible articles published between January 
1996 and June 2012 that met our inclusion criteria. We combined these published 
datasets with 29 eligible, unique datasets from year-round, influenza hospital-based 
surveillance. These combined data covered 50 countries with varying income and vaccine 
policies. Extracting numbers tested and positive for influenza, we calculated crude 
median positive proportions and evaluated potential differences in crude proportions 
among variables using Kruskal-Wallis non-parametric tests. We observed differences by 
data source and country development status when we included the 2009 pandemic year. 
With the exclusion of the 2009 pandemic year, we then generated adjusted pooled 
estimates using the log binomial model. We found 11% of cases from adult respiratory 
hospitalizations worldwide were laboratory-confirmed for influenza. This pooled 
estimate was independent of age but increased as country development or income level 
decreased. Our findings suggest that influenza is an important contributor to severe acute 
respiratory illness among both young and older adult populations. For countries without 
reliable influenza data, we provide an estimate that they may use in planning and 
allocating resources for the control and prevention of influenza. 
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Chapter I Introduction 
 
1.1 Background 
 
Respiratory diseases remain the second leading cause of deaths globally. 
Influenza contributes to this global mortality (Ferkol & Schraufnagel, 2014). According 
to the World Health Organization (WHO), an estimated 200,000 to 500,000 deaths and 3 
to 5 million hospitalizations annually are attributable to influenza (WHO, 2014b). This 
burden is due in part to the mutable nature of the influenza virus, which causes seasonal 
epidemics and potentially pandemics (CDC, 2012, 2013). The only current means of 
influenza prevention is through vaccination (CDC, 2012, 2013; Fiore, Bridges, & Cox, 
2009). Although influenza vaccination and other interventions have been associated with 
reductions in influenza disease many countries do not have sufficient evidence on the 
burden of influenza to support the implementation of such interventions (Bresee et al., 
2013; Partridge & Kieny, 2013; Radin et al., 2012).  
High-income, developed countries have found evidence of the high influenza 
disease burdens among young children and older adults, through modeling approaches 
and hospital-based surveillance (W. W. Thompson, Shay, Weintraub, & et al., 2004; 
Zhou et al., 2012). The recent advancement and expansion of both approaches has 
afforded developing countries and countries with complicated influenza seasons the 
ability to monitor influenza disease (Savy et al., 2013; Simmerman & Uyeki, 2008) 
(Gessner, Shindo, & Briand, 2011; Mmbaga et al., 2012; Radin et al., 2012; Savy et al., 
2013). Combining the data from these advancements and from a systematic review, two 
meta-analyses have estimated the global burden of seasonal influenza in pediatric 
respiratory hospitalizations (Lafond et al., 2014; Nair et al., 2011). The meta-analyses 
revealed substantial morbidity among the pediatric population globally (~1 million cases 
of severe acute lower respiratory infections, 374,000 to 870,000 hospitalizations), with 
school-aged children bearing the highest burden (Lafond et al., 2014; Nair et al., 2011). 
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While global burden is not known for adults, certain adult populations are at 
higher risk of disease. Adults who care for ill children or patients are at an increased risk 
of influenza disease (Kuster et al., 2011; Dena L. Schanzer, Langley, & Tam, 2008a; 
Mauskopf, Klesse, Lee, & Herrera-Taracena, 2013). Complications as a result of disease 
have been observed in individuals with underlying conditions (C. Cohen et al., 2012; 
Gessner et al., 2011; Mauskopf et al., 2013; Dena L. Schanzer et al., 2008a).  The 
increased risk of influenza disease and complications associated with disease is especially 
high during pandemics (CDC, 2013; N. J. Cox & Subbarao, 2000; F. S. Dawood et al., 
2012; Kuster et al., 2011; Dena L. Schanzer et al., 2008a). Similarly to previous 
pandemics, an estimated 65% of deaths associated with the 2009 pandemic H1N1 
influenza virus was observed globally among adults <65 years old (N. J. Cox & 
Subbarao, 2000; F. S. Dawood et al., 2012).   
In preparation for future pandemics, WHO is working with country officials and 
stakeholders to increase vaccine supply and to encourage influenza vaccine research and 
development (Friede et al., 2011). With sufficient supply of effective influenza vaccines, 
countries across the global will potentially reduce case-fatalities and prevent the 
breakdown of health and social services (Friede et al., 2011). Research and development 
will lead to improved treatment options, prevention strategies, and diagnostics (Stohr, 
2003; Yu et al., 2014). 
Due to competing priorities and limited resources, many countries have not 
implemented policies to control and prevent influenza disease (Ayele et al., 2012; 
Samaan, McPherson, & Partridge, 2013) leaving their populations susceptible to 
influenza disease (Friede et al., 2011; Partridge & Kieny, 2013). Middle and low income 
countries without established influenza vaccine policies report the largest burden of 
influenza morbidity and mortality within Asia, Africa, and Latin America and the 
Caribbean, and among the pediatric population worldwide (Gessner et al., 2011; Lafond 
et al., 2014; Nair et al., 2011; Savy et al., 2013; Simmerman & Uyeki, 2008). These high 
burden estimates, obtained from hospital-based surveillance and summed through meta-
analyses, may provide the needed evidence to advocate for investments in influenza 
control and prevention measures, which will in turn improve the global pandemic 
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preparedness and response (Friede et al., 2011; Gordis, 2009; Schoub, 2010; WHO, 
2005).  
Although current systematic reviews and meta-analyses shed light on the high 
influenza burdens in developing countries and within the global pediatric population, 
little is known about the global burden of influenza among the adult populations (Gessner 
et al., 2011; Kuster et al., 2011; Dena L. Schanzer et al., 2008a). A recent publication 
suggests higher incidences of respiratory failure due to influenza among hospitalized 
adults than among pediatric patients (Ortiz et al., 2013). Through this systematic review 
of published and unpublished influenza-associated hospitalization datasets, we provide an 
estimate for the global burden of influenza among adult respiratory hospitalizations. This 
estimate may be used to guide influenza policy, assisting the needs assessment for 
interventions, in countries without reliable influenza data, and to support global programs 
that establish and sustain influenza surveillance, laboratory testing, and vaccine 
manufacturing capacity.  
 
1.2 Purpose of study 
 
 The purpose of this study is to estimate the global proportion of influenza in adult 
acute respiratory hospitalizations through a systematic review. 
  
1.3 Research questions: 
 
1. What is the estimated global proportion of adult (≥18 years old) acute respiratory 
hospitalizations due to seasonal influenza? 
2. Of these hospitalizations, is a higher influenza-positive proportion observed 
among older adults (≥65 years old) than younger adults (18-64 years old)? 
3. Do influenza positive proportions differ by WHO regions? 
4. Do the positive proportions vary by country income levels and/or developmental 
status? 
5. Due to the variability of laboratory tests (differences in sensitivity and specificity 
between different laboratory tests) and clinical presentations, do the test 
performance and/or case definitions impact the positive proportions? 
6. How does the pandemic H1N1 data impact the positive proportions? 
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Chapter II Literature Review 
 
Influenza has caused morbidity and mortality throughout the centuries globally. The 
first documented influenza pandemic was in 1580 (CDC, 2012). An estimated 20-30 
million or more deaths resulted from the Spanish influenza pandemic in 1918 (CDC, 
2012). In 2009, approximately 60 million cases of pandemic influenza A (H1N1) were 
reported in the United States alone (CDC, 2012). Of these cases, 270,000 were 
hospitalized and 12,500 died (CDC, 2012). Other influenza pandemics occurred in 1957 
(H2N2) and 1968 (H3N2, WHO 2005). During non-pandemic years, “seasonal” influenza 
viruses contribute to morbidity and mortality worldwide (L. Simonsen et al., 1997). 
Viboud et al. estimated that 1 million annual deaths worldwide are attributable to 
influenza (Cécile Viboud, Alonso, & Simonsen, 2006). 
 
2.1 Influenza Viruses 
 
Influenza is a single-stranded RNA virus of the Orthomyxovirus family (CDC, 2012). 
Three types of influenza cause disease in humans—type A, B, and C (CDC, 2012). Type 
C is thought to be the least virulent, typically causing subclinical infections in children 
and young adults (CDC, 2012; Greenbaum, Morag, & Zakay-Rones, 1998; White & 
Fenner, 1994).  Greenbaum et al and others report sporadic cases of influenza type C 
during influenza types A and B outbreaks (Greenbaum et al., 1998; Taylor, 1951).   
In recent years, the burden of influenza type B illness has reportedly increased in the 
United States and the United Kingdom (W.P. Glezen, Schmier, Kuehn, Ryan, & Oxford, 
2013). Type B viruses are divided into two genetic lineages, Victoria and Yamagata 
(CDC, 2012, 2013). These lineages may co-circulate (CDC, 2013). In vitro analysis 
suggests that type B is a more stable virus, with a slower mutation rate than type A 
(CDC, 2013; W.P. Glezen et al., 2013); the same lineage (Victoria) included in the 
trivalent vaccine for last 10 years (CDC, 2013). Five of those ten years, the vaccine 
lineage was predominant (CDC, 2013). While lineage is the same, the vaccine strain 
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changes similarly to type A subtypes (WHO, 2014c). Generally, type B infections are 
primarily found in children (CDC, 2013).   
  Type A is categorized into subtypes by surface antigens, hemagglutinin (HA) and 
neuraminidase (NA) (CDC, 2012, 2013; White & Fenner, 1994). HA (H1-16) promotes 
viral attachment to host cell, while NA allows the virus to penetrate the cell (CDC, 2012, 
2013; White & Fenner, 1994). HA in human flu viruses are genetically similar to those 
isolated from birds and pigs (CDC, 2013). In 2013, human cases of H7N9, resulting from 
a triple assortment, were identified and thought to be associated with open markets 
selling birds (Liu et al., 2014).   
Influenza viruses undergo frequent antigenic change during viral replication 
(CDC, 2013). Small changes occur within the genes coded for the antigen-binding sites 
of the virus, known as antigenic drift (CDC, 2012, 2013). Antigenic drift may lead to 
epidemics, since these changes may result in a new, unrecognizable virus to the host’s 
immune system (CDC, 2012). Epidemics are reported annually for types A and B (CDC, 
2012, 2013; W.P. Glezen et al., 2013). In the United States, annual influenza epidemics 
account for 114,000 hospitalizations and 20,000 deaths (Brammer et al., 2002). Type A 
viruses experience antigenic drift more frequently and more rapidly than types B (CDC, 
2013).  Type A viruses may also undergo recombination events, where not seen before 
surface antigens arise (CDC, 2012, 2013; White & Fenner, 1994). This phenomenon is 
known as antigenic shift (CDC, 2012, 2013; White & Fenner, 1994). Antigenic shift 
promotes the greatest change potentially resulting in pandemics where little or no pre-
existing immunity exists and when the new virus effectively transmits from human to 
human (CDC, 2013). Antigenic shifts are thought to occur approximately every 20 years, 
while antigenic drifts occur all the time (CDC, 2012). Pandemics have higher attack rates 
than epidemics (CDC, 2012, 2013).  Gordan et al found attack rates doubled for 
pandemic H1N1 (20.1%) in comparison to the 2007 seasonal influenza (11.7%) among 
children in Nicaragua (Gordon et al., 2010). While severe disease during annual 
epidemics often disproportionately affects certain age groups (<5 and ≥65 years old) and 
individuals with comorbidities, pandemics have a wider impact across age groups and 
health statuses, including healthy young individuals (CDC, 2012; WHO, 2012a). 
However, seasonal epidemics can occasionally cause spikes in severe respiratory illness 
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in young, healthy individuals as well, as observed in the 2003-2004 season (CDC, 2014a; 
WHO Collaborating Center for Surveillance et al., 2004).      
 
2.2 Transmission, Clinical Presentations, and Diagnosis 
 
The main mode of influenza transmission is through direct or indirect, via 
contaminated object, contact with respiratory droplets from an infected individual 
(Weinstein, Bridges, Kuehnert, & Hall, 2003).  One to four days after contact, newly 
infected individuals may exhibit the classic influenza symptoms: abrupt onset of fever, 
myalgia, sore throat, nonproductive cough, and/or headache (CDC, 2012). These 
symptoms are often used to describe other pathogenic infections (CDC, 2012; Harper et 
al., 2009; Weinstein et al., 2003). Influenza infections are generally self-limiting and can 
be asymptomatic (Harper et al., 2009). In fact, 50% of influenza-infected individuals 
present symptoms (CDC, 2012). The clinical course of influenza infections depend on the 
individual’s health as well as on the circulating influenza strain (CDC, 2012). Influenza 
infections may progress to severe pneumonia, primary influenza pneumonia or secondary 
bacterial pneumonia (Bader & McKinsey, 2005; CDC, 2012). Influenza was identified as 
one of the leading causes of community acquired pneumonia hospitalizations among 
adults in Vietnam and acute respiratory illness case-fatalities among adults in Guatemala 
(Takahashi et al., 2013; Verani et al., 2013). Influenza infections have led to the 
exacerbations of underlying medical conditions, such as myocarditis and chronic 
pulmonary diseases (CDC, 2012; Harper et al., 2009; Dena L. Schanzer, Langley, & 
Tam, 2008b).  
  As influenza illness presents similarly to many other respiratory pathogens and 
cannot be diagnosed by clinical presentation alone, infection needs to be confirmed 
through laboratory testing (Weinstein et al., 2003). These laboratory tests may include 
viral culture, direct or indirect immunofluorescence, serology (such as antigen 
complement fixation assay, hemagglutination inhibition assay, and enzyme-linked 
immunosorbent assays), single or multiplex polymerase chain reaction (PCR), and rapid 
antigen tests (Kumar & Henrickson, 2012; Talbot & Falsey, 2010). Laboratory tests vary 
in required technical skills and/or specialized equipment, turnaround times, as well as 
sensitivity and specificity for influenza detection (Kumar & Henrickson, 2012; Talbot & 
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Falsey, 2010). Despite these differences, all tests are limited in their ability to detect 
influenza virus by the time from illness onset to of specimen collection as peak shedding 
occurs early in infection, and by the handling and storage of specimen (Lau et al., 2010) 
(Carrat et al., 2008; Kumar & Henrickson, 2012).   
 
2.3 General Epidemiology 
 
Circulation of influenza viruses 
The dominant circulating influenza type and/or subtype may change from year to 
year and vary in disease severity. Prior to pandemic H1N1, higher influenza-associated 
mortality rates were reported when type A H3N2 predominately circulated than when 
type A H1N1 or type B predominately circulated (CDC, 2010; Kyncl et al., 2005; L. 
Simonsen et al., 1997; W. W. Thompson et al., 2009). Following the pandemic H1N1 in 
2009, in 2010, influenza B was the virus type in eastern Asia, and northern and eastern 
Europe (WHO, 2010). In Southeast Asia and in Africa, pandemic type A (H1N1) 
remained predominant with type B and type A H3N2 co-circulating (WHO, 2010). 
Influenza peaks during the winter months in temperate regions (November 
through March in the northern hemisphere and April through September in the southern 
hemisphere); these periods are marked by an increase in medical visits for classic 
influenza-like symptoms (fever and cough and/or sore throat) (CDC, 2012; N. J. Cox & 
Subbarao, 2000). This may be due to the fact that the influenza virus survives longer 
outside of the host in cold and dry weather (Cécile Viboud et al., 2006; WHO, 2014b). 
Peaks of influenza occur year-round in tropical and subtropical regions (CDC, 2012; N. J. 
Cox & Subbarao, 2000; Cécile Viboud et al., 2006).  
 
 Risk factors associated with severe outcomes due to seasonal influenza   
Influenza viruses cause disease in all ages (CDC, 2013). Illness due to influenza, 
as described earlier, is generally mild, not requiring medical attention (CDC, 2012, 
2013). Some cases, however, do lead to severe outcomes, such as hospitalization and/or 
death. From influenza mortality and morbidity rates, studies have shown that certain age 
groups and people with comorbidities are at an increased risk of severe influenza-
associated outcomes (CDC, 2012, 2013). 
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During a typical influenza season, a U-shaped distribution curve is observed 
among the age groups, where the highest number of influenza-attributable 
hospitalizations and deaths are reported for children <5 years old and adults ≥65 years old 
(CDC, 2013; C. Viboud et al., 2004). Functionality of the host immune system may play 
a role; young children lack immunity while older adults are unable to mount adequate 
protective immune response against the circulating influenza virus (CDC, 2013; Haq & 
McElhaney, 2014; Sambhara & McElhaney, 2009). Immune functionality is further 
decreased in children and adults with underlying medical conditions (CDC, 2013).  
Medical conditions, such as chronic cardiovascular disease and chronic 
respiratory disease, may worsen when individuals become ill due to influenza (Madjid, 
Aboshady, Awan, Litovsky, & Casscells, 2004; Mauskopf et al., 2013; Dena L. Schanzer 
et al., 2008a; Siriwardena, 2012). Within 3 days of influenza infection, individuals with 
cardiovascular disease are 4-times more likely to experience myocardial infarction and 
stroke (Smeeth et al., 2004). Influenza infections increase the incidence of secondary 
bacterial infections in patients with chronic obstructive pulmonary disease (COPD), 
leading to longer hospitalization stays and greater lung impairment (Mallia & Johnston, 
2007). Influenza infections exacerbate wheezing and asthma in young children (Patria, 
Tenconi, & Esposito, 2012). Neurological diseases, diabetes, chronic renal disease, 
morbid obesity, and compromised or suppressed immune systems due to HIV, 
transplants, or chemotherapy have also been linked to influenza-related complications 
(CDC, 2013; C. Cohen et al., 2012; Mauskopf et al., 2013). 
Pregnant or recently pregnant women have also shown to be at increased risk of 
complications due influenza infections (CDC, 2013; Laibl & Sheffield, 2005; WHO, 
2012a). Secondary bacterial infections are common among pregnant women in their third 
trimester and postpartum women within 4 weeks after delivery (Laibl & Sheffield, 2005). 
Some studies report increased delivery complications in pregnant women hospitalized for 
influenza infection (CDC, 2013). 
Due to the nature of their job, healthcare workers are at an increased risk of 
influenza infections (CDC, 2013; Kuster et al., 2011).  Kuster et al calculated this risk as 
a 2.5 fold increase in healthcare workers compared to adults not working in the 
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healthcare field (Kuster et al., 2011). Healthcare workers may also spread influenza to 
vulnerable patients (Kuster et al., 2011). 
                                   
Prevention  
Although good hygiene assists in preventing influenza transmission, the only and 
most effective method of influenza prevention is through vaccination (CDC, 2010, 2013; 
Fiore et al., 2009). Current vaccines available in the United States are the inactivated 
influenza vaccine (administered  to anyone ≥6months without contradictions); live, 
attenuated, cold adapted influenza vaccine (LAIV, administered via nasal spray to only 
children 2-8 without aspirin-regiments or respiratory conditions (asthma or wheezing)); 
the inactivated influenza vaccine with a higher dose of hemagglutinin  (available as 
another option for adults >65 years old);  and trivalent recombinant influenza vaccine and 
cell-based inactivated influenza vaccine (as options for individuals with an egg allergy) 
(Fiore et al., 2009; Grohskopf et al., 2014). Inactivated influenza vaccines may be 
formulated to protect against three (trivalent) or four (quadrivalent) different influenza 
viruses (CDC, 2014b; Grohskopf et al., 2014). Vaccine effectiveness is not 100%; it 
depends on age, immune status, and the antigenic similarity between the circulating and 
vaccine strains (Harper et al., 2009). Reduction in vaccine effectiveness has been 
reported in older adults, >65 years old, with or without comorbidities, and 
immunocompromised patients (Jansen, Sanders, Hoes, van Loon, & Hak, 2007; Lenglet 
et al., 2007; Mauskopf et al., 2013; Sambhara & McElhaney, 2009). Despite the reduced 
effectiveness, studies have shown that immunizing older adults reduced influenza-
associated hospitalizations (Jansen et al., 2007; Jefferson et al., 2010).  This effectiveness 
is only seen when vaccine strains antigenically match the strains in circulation (Fiore et 
al., 2009). Due to the constant antigenic changes that influenza viruses undergone, one or 
more strains included in the vaccine change annually (CDC, 2012, 2013).       
    
Treatment  
 Although treatment is not usually recommended for self-limited influenza 
infection, antivirals are available and recommended for influenza-infected individuals 
who are at high risk of developing complications (Harper et al., 2009). Early treatment, 
within 48 hours of onset, with antivirals has shown to reduce severity and duration of 
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influenza infections (CDC, 2010; Harper et al., 2009). Current antivirals target viral 
infection, the release of viral particles and viral replication (Gu, Liu, & Wei, 2013; 
Michiels, Van Puyenbroeck, Verhoeven, Vermeire, & Coenen, 2013).  Neuraminidase 
inhibitors, oseltamivir and zanamivir, are the only antivirals available in the United States 
(CDC, 2012). Studies show that oseltamivir and zanamivir are effective against influenza 
types A and B (CDC, 2012; Harper et al., 2009). Their effectiveness against type A 
viruses may be subtype-specific (Harper et al., 2009). M2 proton channel inhibitors, 
amantadine and rimantadine, have been used in the past to treat non-pandemic A 
(H1N1viruses) (Harper et al., 2009). Since strains circulating in the United States and 
worldwide have shown resistance to amantadines and rimantadines, these antivirals are 
not currently recommended (CDC, 2012). The decision to use antivirals for the 
prophylaxis or treatment of influenza-like-illness often depends on if the benefits 
outweigh the risks (virus strain resistance, side-effects, and financial costs) (Michiels et 
al., 2013).     
 
2.4 Burden of Influenza Disease 
 
 Burden of disease is the measure of impact that a pathogen has on a population 
(Gordis, 2009). This impact includes morbidity and mortality—from the very mild 
disease to severe disease to death (Gordis, 2009). Different methods and tools are used to 
quantify this impact (Gordis, 2009; Lozano et al., 2012; Parashar, Hummelman, Bresee, 
Miller, & Glass, 2003).Quantifying the burden allows leaders to see if efforts or 
additional efforts are needed in developing interventions (Gordis, 2009; Lozano et al., 
2012; Parashar et al., 2003).  
Influenza disease severity varies. Most often, influenza disease is self-limiting and 
does not require medical attention (CDC, 2012; Harper et al., 2009). To capture these 
mild cases, epidemiologists issue household or serum surveys (CDC, 2012). Sudden 
increases in outpatient visits usually coincide with annual influenza epidemics (CDC, 
2012, 2013; N. J. Cox & Subbarao, 2000; W. P. Glezen, Payne, Snyder, & Downs, 1982). 
Surveillance systems may be developed to systematically collect, analyze, and interpret 
outpatient, inpatient, and mortality data (CDC, 2012; Gordis, 2009). From the synthesis 
of the influenza surveillance data, epidemiologists calculate the estimates of excess 
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influenza-associated mortality, influenza-associated hospital morbidity, and direct and 
indirect costs associated with medical care and/or loss time due to influenza infections 
(CDC, 2012).  
 
Excess influenza-associated mortality 
Influenza infections may go untested, undiagnosed, and underreported for various 
reasons (Azziz-Baumgartner et al., 2013). Testing can be resource intensive (Layne, 
2006; Schoub, 2010). When testing is completed, the results are not always available for 
clinical management, and a positive test may not alter the treatment plan, especially for 
mild cases (Azziz-Baumgartner et al., 2013). Due to incomplete identification and 
varying severity of influenza infections, epidemiologists rely on statistic modeling for 
estimating disease burden of influenza (CDC, 2010; Lopez-Cuadrado, de Mateo, 
Jimenez-Jorge, Savulescu, & Larrauri, 2012; L. Simonsen et al., 1997). This approach 
was introduced by William Farr during the 1847-1848 influenza epidemic in London (L. 
Simonsen et al., 1997).  Early epidemiologists, such as William Farr, calculated simple 
excess mortality estimates as differences in the number of deaths between time periods 
where influenza is present and where influenza is absent (L. Simonsen et al., 1997). 
Initially, these modeling techniques were limited to regions with defined influenza 
seasons and countries with established vital statistics (Cécile Viboud et al., 2006). Since 
influenza often circulates throughout the year in tropical and subtropical regions, it is 
more difficult to establish a baseline, a period of non-influenza activity, which is essential 
for this approach (Cécile Viboud et al., 2006). Influenza-associated deaths are obtained 
from deaths coded for pneumonia or influenza by the International Classification of 
Diseases, ICD-10: J00-J99 for instance (Gordis, 2009; D. L. Schanzer, Sevenhuysen, 
Winchester, & Mersereau, 2013), although alternative approaches also include deaths due 
to respiratory and circulatory diseases, and in some cases, all-cause deaths accounting for 
severe influenza infections complicated by underlying conditions and secondary bacterial 
infections. Vital registration records, however, do not capture all the deaths (Lozano et 
al., 2012). In 2005, 18.8 million of 51.7 million deaths were recorded (Lozano et al., 
2012). Coding regulations and categories change often, which may lead to inaccurate 
estimations of influenza-associated deaths (Barker & Mullooly, 1981; W. P. Glezen et al., 
1982). 
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Since 1889, the United States and Western Europe have been tracking influenza- 
associated mortality (Monto, 2004). Earlier modeling techniques did not account for 
deaths due to co-circulating pathogens, such as respiratory syncytial virus, and lacked 
confirmation of influenza infection (Yang, Chiu, et al., 2011). With advancements in 
diagnostics, surveillance networks were established and reliable influenza activity 
became available (Lopez-Cuadrado et al., 2012; Yang, Chiu, et al., 2011). Serfling 
regression, poisson regression, negative binomial regression, and generalized linear 
regression are models used to calculate influenza-associated mortality (Lopez-Cuadrado 
et al., 2012; W. W. Thompson et al., 2009). The Poisson or generalized linear regression 
models allowed epidemiologists to account for changes in population size, to incorporate 
other factors (such as temperature or co-circulating pathogens), and to assess disease 
severity by virus type and/or subtype (Freitas et al., 2013; Lopez-Cuadrado et al., 2012; 
W. W. Thompson, Comanor, & Shay, 2006; W. W. Thompson et al., 2009). These 
advanced statistical models require consistent, robust weekly viral surveillance data and 
at least 5 years of mortality data (W. W. Thompson et al., 2009). The quality and quantity 
of available mortality data and influenza surveillance data vary by region and country 
(Gordis, 2009; D. L. Schanzer et al., 2013; W. W. Thompson et al., 2009). Other 
statistical models, such as rate difference and autoregressive integrated moving average 
(ARIMA), do not require virological data or manually setting baselines (W. W. 
Thompson et al., 2009). Rate difference and ARIMA may serve as options for countries 
with limited viral surveillance and complex influenza seasons (W. W. Thompson et al., 
2009). In a comparison of four different models using the same data, Thompson et al 
found that annual influenza-associated death estimates were similar among the models 
except for summer-season rate difference model and ARIMA, which were consistently 
higher (W. W. Thompson et al., 2009). Schanzer et al found that different models of 
Poisson regression (multiplicative, additive, negative binomial distribution) produced 
almost identical results (D. L. Schanzer et al., 2013). Influenza-associated mortality 
estimates from various models and regions are listed in the table below. 
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Table of Influenza-associated Excess Mortality 
Country Study 
period 
Statistical Method Underlying 
pneumonia/ 
influenza (per 
100,000 person-
years) 
Underlying 
respiratory/ 
circulatory 
deaths (per 
100,000 person-
years) 
All-cause 
deaths 
Southern Brazil 
(Freitas et al., 
2013) 
1980-
2008 
Serfling regression 
model using monthly  
number of deaths 
All ages: 1.4 
≥60yr: 10.0 
 
All ages: 9.2 
≥60yr: 86.6 
 
Singapore 
(Chow, Ma, 
Ling, & Chew, 
2006) 
1996-
2003 
Negative binomial 
regression using 
monthly number of 
deaths and monthly 
proportion of 
influenza-positive test 
result 
All ages: 2.9 
≥65yr: 46.9 
All ages: 11.9 
≥65yr: 155.4 
 
Hong Kong (C.-
M. Wong, Chan, 
Hedley, & Peiris, 
2004) 
1996-
1999 
Poisson regression 
model using weekly 
number of deaths and 
weekly proportion of 
influenza-positive test 
result 
All ages: 4.1 
≥65yr: 39.3 
All ages: 12.4 
≥65yr: 102.0 
 
USA (CDC, 
2010) 
1976-
2007 
Poisson regression 
model using weekly 
number of deaths and 
weekly influenza-
positive proportion  
All ages: 2.4 
<19yrs: 0.1 
19-64yrs: 0.4 
≥65yr: 17.0  
 
All ages: 9.0 
<19yrs: 0.2 
19-64yrs: 1.5 
≥65yrs: 66.1 
 
South Africa 
(Cheryl Cohen et 
al., 2010) 
1998-
2003 
Serfling regression 
model using monthly 
number of deaths 
≥65yr: 42.0   
Argentina 
(Azziz-
Baumgartner et 
al., 2013) 
2002-
2009 
Linear regression 
model/Serfling using 
deaths  
All ages: 6.0 
men≥65yr: 37 
women ≥65yr: 
36 
men <65yr: 2 
women <65yr: 1 
2009 H1N1, 
<65: 8 
(compared to 
seasonal periods, 
3) 
All ages: 21.4 
men≥65yr: 171 
women ≥65yr: 
136 
men <65yr: 4 
women <65yr: 2 
2007 (H3N2), all 
ages: 34  
flu A (H1N1) or 
flu B seasons, all 
ages: 11.4 to 
23.4 
 
East and 
Southeast Asia 
(Guangzhou, 
Hong Kong, and 
Singapore)(Yang, 
Ma, et al., 2011) 
2004-
2006 
Poisson regression 
model using weekly 
number of deaths 
(natural spline 
smoothing function of 
time, temperature, and 
relative humidity)  
Guangzhou 
All ages: 1.0 
 
Hong Kong 
All ages: 4.6 
 
Singapore 
All ages: 2.8 
Guangzhou 
All ages: 9.8 
>65yr: 104.1 
Hong Kong 
All ages: 9.5 
>65yr: 78.7 
Singapore 
All ages: 5.3 
>65yr: 46.0 
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Country Study 
period 
Statistical Method Underlying 
pneumonia/ 
influenza (per 
100,000 person-
years) 
Underlying 
respiratory/ 
circulatory 
deaths (per 
100,000 person-
years) 
All-cause 
deaths 
Canada (D. L. 
Schanzer et al., 
2013) 
1992-
2009 
Poisson regression 
model using weekly 
deaths (vital statistics) 
and hospitalization 
discharge records 
All ages: 11.3 
(fluA H3N2, 
H1N1, and 
pH1N1) 
Only pH1N1 
All ages: 1.7 
<65 yrs: 0.9 
65+ yrs: 0.6 
  
Canada (Dena L. 
Schanzer et al., 
2008a) 
1994 – 
2000 
Poisson regression 
model using weekly 
death (vital statistics) 
and hospital discharge/ 
admission records and 
database (identified 
individuals with 
comorbidities) 
  All ages: 14 
<50yrs: 0.3 
50-54yrs: 3 
55-59yrs: 4 
60-65yrs:10 
65-69yrs: 2 
70-74yrs: 34 
75-79yrs: 89 
80-84yrs: 175 
85-89yrs: 387 
90+yrs: 831 
65+yrs: 96 
Spain (Lopez-
Cuadrado et al., 
2012) 
1999 – 
2005 
Serfling using only 
national vital statistics; 
Poisson regression 
model using vital 
statistics and viral 
surveillance 
Serfling 
>44yrs:2.68 
45-64yrs: 0.33 
>64yrs: 15.25 
 
GLM 
>44yrs:1.08 
45-64yrs: 0.18 
>64yrs: 6.00 
 Serfling 
>44yrs:30.42 
45-64yrs: 
3.77 
>64yrs: 
164.10 
 
GLM 
>44yrs:10.97 
45-64yrs: 
2.31 
>64yrs: 57.05 
USA (W. W. 
Thompson et al., 
2003) 
    All ages: 19.6 
Portugal (Nunes 
et al., 2011) 
1980 – 
2004  
 All ages: 1.45  All ages: 13 
Czech Republic 
(Kyncl et al., 
2005) 
1982 – 
2000  
Serfling with poisson 
distribution using 
weekly number of 
deaths (vital statistics) 
and viral surveillance 
data 
  All ages: 
25.99 
Italy (Rizzo et 
al., 2007) 
1969 – 
2000  
 All ages: 3   
 
Influenza-associated excess mortality rates vary by age and health status. The 
highest influenza-associated excess mortality rates are observed among adults older than 
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65 years of age. In fact, 90% of influenza-associated deaths reported in the United States 
were identified in the older age group (CDC, 2010).Singapore also reported an 11.3 times 
higher risk for influenza-related mortality in older adults than in the general population 
(Simmerman & Uyeki, 2008). Schanzer et al found that age as well as underlying 
conditions, especially chronic lung or heart disease, contributed independently to elevate 
risks of influenza-associated mortality (Dena L. Schanzer et al., 2008a). Estimated excess 
influenza-associated mortality were also elevated in individuals infected with human 
immunodeficiency (C. Cohen et al., 2012), 94-146/100,000 estimated excess influenza-
associated mortality compared to 0.9-1.0 in general population between 25-64 years of 
age and 64-70 deaths in adults ≥65 years old (CDC, 2010).     
  
Influenza-associated hospital morbidity 
 Mortality only accounts for a small portion of severe influenza cases (Lenglet et 
al., 2007; Lone Simonsen, Fukuda, Schonberger, & Cox, 2000). Hospitalizations make up 
an important component of influenza disease burden, and these individuals may present 
atypical influenza symptoms and therefore are not tested for influenza (Lenglet et al., 
2007; W. W. Thompson et al., 2004; Yang, Chiu, et al., 2011; Zhou et al., 2012). Since 
testing for influenza is not routine, even hospitalized patients with influenza symptoms 
may not be tested for influenza (Wang et al., 2012; Yang, Chiu, et al., 2011; Zhou et al., 
2012). In attempts to overcome these limitations and indirectly estimate the burden of 
influenza hospitalizations, modeling approaches similar to those used to estimate excess 
influenza-associated mortality, can be used (Kim, Kilgore, Lee, Nyambat, & Ki, 2011; 
Yang, Chiu, et al., 2011). The total number of hospitalizations during and outside of an 
influenza season can be obtained from hospital or health insurance discharge databases 
(Gordis, 2009; Kim et al., 2011). These databases are usually unavailable in lower-middle 
and low income countries (Gordis, 2009). Since hospital discharge records utilize a 
similar international coding system as death certificates, they are subject to the same 
coding changes, possible misclassifications, and differences in usage by various 
healthcare systems (Jansen, Sanders, Hoes, van Loon, & Hak, 2007; Kim et al., 2011; 
Perrotta, Decker, & Glezen, 1985). Records may be incomplete in the description of 
patient conditions, excluding underlying conditions, possible co-infections, and vaccine 
status (Gordis, 2009; Kim et al., 2011; Zhou et al., 2012). To limit underestimations of 
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influenza-associated hospitalizations as a result of incomplete records, some models 
expanded the list of codes used to define an influenza-associated hospitalization, 
‘pneumonia and influenza’ to ‘respiratory and circulatory diseases’ for example. These 
models and other models may have included viral surveillance data for confirming 
influenza seasons and for taking into account co-circulating viruses (Kim et al., 2011; 
Jansen, Sanders, Hoes, van Loon, & Hak, 2007).  The table below presents influenza-
associated hospitalization rates resulting from these various models. 
Table of Influenza-associated Hospitalizations 
Country 
(source) 
Study 
Period 
Data Source Method Estimated Hospitalization Rates 
Hong Kong 
(C. M. Wong 
et al., 2009) 
1996-
2000 
Hospital 
discharge 
diagnoses from 
14 acute 
hospitals 
Poisson 
regression 
weekly 
counts 
(control for 
RSV)  
29.3 excess pneumonia & influenza per 
100,000 (all age groups) 
11.6% of all hospitalizations 
Excess influenza-associated 
hospitalizations coded as acute respiratory 
disease  
0-14yrs: 163.3 (135.2, 189.7) 
15-39yrs: 6.0 (2.7, 8.9) 
40-64yrs: 14.9 (10.7, 18.8) 
65-74yrs: 83.8 (61.2, 104.2) 
75+ yrs: 266 (198.7, 330.2) 
All: 60.6 (52.8, 67.2)  
Hong Kong 
(C. M. Wong 
et al., 2012) 
2005-
2010 
Electronic 
hospital 
discharge 
records from 41 
hospitals 
quasiPoiss
on 
regression 
models 
Seasonal rates of excess influenza-
associated hospitalizations 
Pneumonia/influenza     Acute Respiratory    
0-5yrs: 23%                                  12.8% 
6-17yrs: 18.3%                             15.5% 
18-39yrs: 9.5%                             10.4% 
40-64yrs: 6.8%                             8.3% 
65-74yrs: 6.3%                             7.1% 
75+yrs: 6.2%                                6.7% 
All ages: 8.5%                              8.8% 
United States 
(W. W. 
Thompson et 
al., 2004) 
1979 - 
2001 
National 
Hospital 
Discharge 
Survey data and 
WHO 
Collaborating 
Labs influenza 
Surveillance 
data 
Poisson 
regression  
Excess pneumonia & influenza 
hospitalizations 
8.6% of all hospitalizations 
<5yrs: 18.5/100,000 
5-49yrs: 6.8/100,000 
50-64yrs: 37.9/100,000 
65-74yrs: 97.3/100,000 
75+yrs: 344.1/100,000 
All ages: 36.8/100,000 
Excess influenza-associated 
hospitalizations coded for respiratory and 
circulatory diseases 
<5yrs: 107.5/100,000 
5-49yrs: 20.8/100,000 
50-64yrs: 83.3/100,000 
65-69yrs: 189.7/100,000 
70-74yrs: 321.2/100,000 
75-79yrs: 431.1/100,000 
17 
 
Country 
(source) 
Study 
Period 
Data Source Method Estimated Hospitalization Rates 
United States 
(W. W. 
Thompson et 
al., 2004) 
1979 - 
2001 
 Poisson 
regression  
80-84yrs: 686.1/100,000 
85+yrs: 1194.9/100,000 
All ages: 88.4/100,000 
United States 
(Lone 
Simonsen et 
al., 2000) 
1970 - 
1995 
National 
Hospital 
Discharge 
Survey Data 
 ~3 million excess P&I hospitalizations 
≥65yrs: 174/100,000 
<65yrs: 33/100,000 
United States 
(Zhou et al., 
2012) 
1993 - 
2008 
Statewide 
hospital 
discharge 
database (13 
states, 40% of 
population); 
influenza and 
RSV viral 
surveillance data 
Negative 
binomial 
regression 
model 
weekly   
Excess influenza-associated respiratory 
and circulatory hospitalizations   
<1yrs: 151/100,000 
1-4yrs: 38.8/100,000 
5-49yrs: 16.8/100,000 
50-64yrs: 65.6/100,000 
65+yrs: 309.1/100,000 
All ages: 63.5/100,000 
Netherlands 
(Jansen, 
Sanders, Hoes, 
van Loon, & 
Hak, 2007) 
1997- 
2003 
hospitalization 
discharge (viral 
surveillance for 
flu and RSV) 
Rate-
difference 
models  
Rates of hospitalizations for influenza-
associated all-cause mortality  
0-17yrs: 14% 
18-49yrs: 12% 
50-64yrs: 23% 
65yrs+: 51% 
(H3N2 most seasons, 2000/01 H1N1) 
Finland (Jacks, 
Ollgren, 
Ziegler, & 
Lyytikainen, 
2012) 
1996- 
2009 
Annual national 
discharge 
register 
(including 
weekly reports 
of seasonality, 
RSV, M. pna) 
Negative 
binomial 
regression 
model  
Rates = “pneumonia & influenza 
coded”/100,000 of age group pop/week 
           2009      Pre-pandemic (1996-2009) 
0-4yrs: 16.6                     15.2  
5-24yrs: 3.5                      2.3 
25-64yrs: 6.7                    5.1 
≥65yrs: 46.5                    47.3 
All ages: 13.4                  11.5 
South Korea 
(Kim et al., 
2011) 
2002- 
2005 
National health 
insurance 
databases 
Rate-
difference 
models 
Rates of hospitalizations coded for 
pneumonia & influenza per year (all ages 
groups): 4.61% (2002), 4.47% (2003), 
4.46% (2004), 4.64% (2005) 
Per 1000 
              2002:          2003:           2004:  
<5yrs:    36.7             41.2            45.8 
5-14yrs:   3.3             5                  3.2 
15-49yrs: 0.9             0.9               0.9 
50-64yrs: 3.1             3                  3.5 
65-74yrs: 8.4             8.4               10.4 
≥75yrs:  15.6             16.9             21.6 
All ages:  4.6             5.1               5.3 
Spain (Lenglet 
et al., 2007) 
2000- 
2004 
Hospitalization 
discharge 
Poisson 
regression 
model  
Influenza-associated hospitalization for 
all-caused mortality  
All ages by season: 
2001/02: 24.7/100,000 
2002/03: 18/100,000 
2003/04: 17.7/100,000 
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Country 
(source) 
Study 
Period 
Data Source Method Estimated Hospitalization Rates 
Canada (Dena 
L. Schanzer et 
al., 2008b) 
1994-
2000 
Hospitalization 
database 
including 
clinical 
diagnostics 
Poisson 
regression 
model 
Hospitalizations coded for influenza & 
pneumonia 
20-49yrs: 1-2/100,000 
50-64yrs: 5-7/100,000 
65+yrs: 37-36/100,000 
20+yrs: 6-8/100,000 
Canada (D. L. 
Schanzer et 
al., 2013) 
1992-
2009 
Hospitalization 
discharge 
records 
Poisson 
regression 
model  
Hospitalizations coded for influenza & 
pneumonia 
Seasonal average due to H3N2, H1N1, 
pH1N1 
All ages: 39.5/100,000 
Argentina 
(Azziz-
Baumgartner 
et al., 2013) 
2005-
2008 
Government-
operated hospital 
discharge forms  
Serfling 
model (P/I) 
Linear 
regression 
model 
(R/C) 
Hospitalizations coded for influenza & 
pneumonia (P/I) 
All ages: 2.0 
Hospitalizations coded for respiratory and 
circulatory disease (R/C) 
All ages: 5.7/100,000 
2007 (H3N2), all ages: 8.4/100,000 
 
From the studies included in the summary table above, the highest rates of 
influenza-associated hospitalizations were commonly observed among older adults (>65 
years of age) and young children, <5 years of age. Severity of disease was dependent on 
type or subtype; hospitalization rates increased when multiple influenza types or subtype 
H3N2 were in circulation (Azziz-Baumgartner et al., 2013; Dao et al., 2010; W. W. 
Thompson et al., 2004). To validate these influenza-associated hospitalization rates, Zhou 
et al suggested conducting large studies testing hospitalized patients prospectively using 
PCR (Zhou et al., 2012). 
In recent years, laboratory-testing capacity has grown globally (Mmbaga et al., 
2012; Nair et al., 2011; WHO, 2013). The number of countries in Africa completing 
influenza surveillance using PCR has increased from 5 to 15 from the year 2006 to 2011 
(Radin et al., 2012). This increased capacity has improved the understanding of influenza 
epidemiology, allowing for the establishment of influenza seasonality and detection of 
novel influenza circulating strains with pandemic potential (WHO, 2011b). The increased 
capacity has also increased the recognition of influenza infections among children and 
adults in developing countries, adding to the evidence of disease worldwide (Nair et al., 
2011; Takahashi et al., 2013; Verani et al., 2013). Along with increased laboratory 
capacity, the Global Influenza Hospitalization Surveillance Network was recently 
established to evaluate influenza burden among hospitalized patients matching a 
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standardized case definition, to quantify virus type and subtype distribution, and to 
measure vaccine effectiveness (Puig-Barbera et al., 2014). With the expansion of 
laboratory capacity and support of network surveillance, countries have calculated 
laboratory-confirmed influenza-associated hospitalization rates (Chadha et al., 2013; Dao 
et al., 2010; Yu et al., 2014) examples of rates are seen in the following table.  
Country-specific, laboratory-confirmed influenza-associated hospitalization rates 
Country 
Influenza 
Seasons 
Overall 
estimates 
Age-group specific estimates 
USA (Dao 
et al., 
2010)
1 
 
2005-2006  
2006-2007 
2007-2008 
Mean 
 
9.9/100,000 
4.8/100,000 
18.7/100,000  
18-49yrs 
3.6/100,000 
2.5/100,000 
7.3/100,000 
4.5/100,000 
50-64yrs 
7.8/100,000 
4.2/100,000 
14.8/100,000 
8.9/100,000 
65-74yrs 
22.9/100,000 
10.6/100,000 
37.6/100,000 
23.7/100,000 
75+yrs 
65.1/100,000 
22.3/100,000 
116.6/100,000 
68/100,000 
China (Yu 
et al., 
2014) 
 
2010-2011 
2011-2012 
   65+yrs 
141/100,000 
89/100,000 
India 
(Chadha et 
al., 2013)
2 
Entire study 
2009-2010 
2010-2011 
44.1/10,000 15-29yrs 
67.1/10,000 
58.3/10,000 
30-44yrs 
25.2/10,000 
23.3/10,000 
45-59yrs 
18.3/10,000 
28.8/10,000 
60+ 
11.6/10,000 
18.7/10,000 
1
Dao et al study population represents 7% of US population ≥18 years old and from only urban hospitals. 
2
Chadha et al study may not reflect the typical influenza season, since it includes pandemic H1N1. 
 
As seen in the above table, estimated rates based on laboratory-confirmed 
influenza hospitalizations are generally lower than rates estimated by models discussed 
earlier. Models may account for severe influenza cases, especially those with atypical 
symptoms, not tested for influenza, where laboratory-confirmed influenza surveillance 
does not. Depending on the sources used, models may underestimate or overestimate 
influenza associated hospitalizations, either by not accounting for influenza 
hospitalizations due to not fully developed or widespread use of hospital administrative 
databases or including hospitalizations not confirmed for influenza and potentially caused 
by other co-circulating pathogens (Azziz-Baumgartner et al., 2013). In attempt to 
overcome the limitations of earlier models and by laboratory-confirmed surveillance, 
Reed, Biggerstaff, and colleagues have created the multiplier model for estimating local 
influenza morbidity (Biggerstaff et al., 2013; Reed et al., 2009). The multiplier model 
adjusts the laboratory-confirmed cases for the portion of population with influenza who 
did not seek care or provide a specimen, for specimens not sent to the public health 
laboratory or tested for influenza, and for mishandled specimens and/or the delay in 
collection of specimens (Biggerstaff et al., 2013; Reed et al., 2009). These adjustments 
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rely on prior knowledge of population health-seeking behaviors, and influenza testing 
procedures and policies (Biggerstaff et al., 2013; Reed et al., 2009).  
 In addition to modeling, systematic reviews provide an assessment of the 
available knowledge to estimate influenza-associated morbidity and mortality (Gessner et 
al., 2013; W.P. Glezen et al., 2013; Savy et al., 2013; Simmerman & Uyeki, 2008). 
Gessener et al summarized literature findings on seasonal influenza in sub-Saharan 
Africa from 1980 to 2009 (Gessner et al., 2013). Gessner and colleagues found that 
influenza viruses contribute substantially to respiratory infection morbidity and mortality 
for all ages, although little was reported about children older than five years old and 
adults (Gessner et al., 2013). They also noted an eight times greater risk of influenza 
mortality and morbidity when a child was co-infected with the human immunodeficiency 
virus (Gessner et al., 2013). Savy et al completed a similar literature review for Latin 
America and the Caribbean (Savy et al., 2013). According to literature from 1980 to 
2008, Savy et al also found substantial morbidity and mortality due to seasonal influenza 
infections (Savy et al., 2013). Although the percentage of specimens received by testing 
centers was low during this time period, 4.7 to 15.4%, Savy et al calculated 36,080 
influenza-like illnesses per 100,000 annually with a mean hospital stay of 5.8 to 12.9 
days and a mean direct cost of $575 US dollars per confirmed case (Savy et al., 2013). 
Savy et al noted low vaccine uptake in the region (Savy et al., 2013). Low vaccine uptake 
was also observed in East and Southeast Asia, according Simmerman and Uyeki who 
summarized literature findings for this region from 1980 to 2006 (Simmerman & Uyeki, 
2008). Due to high variability between studies, using different case definitions and data 
collection methods, they were unable to aggregate data and calculate estimates 
(Simmerman & Uyeki, 2008). Simmerman and Uyeki, however, found evidence of 
influenza disease throughout the region (Simmerman & Uyeki, 2008). Middle and high 
income countries, with improved and sustained laboratory capacity and surveillance, 
reported the largest burden of influenza morbidity and mortality (Simmerman & Uyeki, 
2008). Higher proportions of the known influenza burden were observed in young 
children and adults >65 years old (Simmerman & Uyeki, 2008). 
To explore the role of influenza in pediatric respiratory hospitalizations globally, 
Nair et al and Lafond et al completed meta-analyses of published and surveillance data 
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(Lafond et al., 2014; Nair et al., 2011). Nair et al estimated 1 million cases of 
hospitalized severe acute respiratory infections in children under five-years-old were 
attributed to influenza each year (Nair et al., 2011). Using the rate-based approach, they 
estimated 28,000 to 111,000 annual influenza-associated deaths (Nair et al., 2011). 
Lafond et al calculated pooled estimates and found that 9.5% of pediatric respiratory 
hospitalizations were due to seasonal influenza infections during the 1996 to 2012 time 
period (Lafond et al., 2014). A higher proportion of influenza associated hospitalizations 
were observed in school-age children (16%) compared to children <5 years-old (6%) 
(Lafond et al., 2014). During seasonal influenza epidemics, adults also experience severe 
outcomes from influenza-related respiratory infections (CDC, 2013; N. J. Cox & 
Subbarao, 2000; F. Dawood et al., 2012). Although Dawood et al found 65% of 
pandemic H1N1 deaths globally were adults 18 to 64 years old in 2009, no global 
estimates for seasonal influenza currently exist for adults (F. Dawood et al., 2012; Kuster 
et al., 2011; Dena L. Schanzer et al., 2008a). 
 
Economic impact of influenza infections 
 After estimating excess mortality and hospital morbidity, a cost analysis 
associated with the disease burden of influenza and with the impact of the targeted 
interventions can be conducted (Azziz-Baumgartner et al., 2013; Szucs, 1999). Influenza 
disease has direct and indirect costs (CDC, 2010; Molinari et al., 2007; Monto, 2004; Ott 
et al., 2013; Peasah, Azziz-Baumgartner, Breese, Meltzer, & Widdowson, 2013; Ryan, 
Zoellner, Gradl, Palache, & Medema, 2006; Szucs, 1999). Physician visits and hospital 
admissions due to influenza infections contribute to high direct costs (Szucs, 1999). In 
France, the use of healthcare services for influenza infections totaled appropriately $300 
million in 1989; the United States reported higher annual direct costs with totals of $1-3 
billion (Szucs, 1999). A larger price tag, however, was observed for indirect costs among 
high income countries (Peasah et al., 2013; Szucs, 1999). Indirect costs, such as 
productivity losses and school or work absenteeism, due to influenza infections totaled 
$2.3 billion in France and $10-15 billion per year in the United States (Szucs, 1999). 
Indirect costs were 50% less than direct costs in Hong Kong and Thailand (Peasah et al., 
2013). Influenza accounts for 10-12% of all sick-related absentees among workers (Ryan 
et al., 2006; Szucs, 1999). An average of 3.7 to 5.9 working days were lost due to 
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laboratory-confirmed influenza infections among healthy working adults (Karve, 
Misurski, Meier, & Davis, 2013; Keech & Beardsworth, 2008). The magnitude of direct 
and indirect costs sharply increases among high risk groups. Influenza infections among 
older adults, for an example, contribute to 64% of the economic burden due to seasonal 
influenza in the United States (Menec, Black, MacWilliam, & Aoki, 2003; Molinari et 
al., 2007). School or work absenteeism was reported highest among closely living 
communities with young children (Szucs, 1999). Individuals with comorbidities 
experience severe influenza outcomes, hospitalizations and deaths, more frequently than 
healthy adults (Dena L. Schanzer et al., 2008a; Szucs, 1999). Interventions, specifically 
influenza vaccination programs, targeting high risk groups have shown to be cost-
effective in the United States and China (Ott et al., 2013; Ryan et al., 2006; Szucs, 1999). 
Vaccinating older adults reduced rates of influenza disease severity (Szucs, 1999). After 
vaccinating healthy adults, rates of absenteeism decreased by 43% and 25% less upper 
respiratory infections were reported (Szucs, 1999). 
Many factors contribute to the cost-effectiveness of influenza vaccination. As 
previously mentioned, vaccine effectiveness varies among age groups and from year to 
year (Fiore et al., 2009; Ott et al., 2013). The timing of vaccination, location of vaccine 
administration, and duration of vaccine protection also impact cost-effectiveness and 
cost-benefit analyses (Ott et al., 2013). Influenza vaccination has been shown to be most 
cost-effective when administrated early in the season (Ott et al., 2013). Due to vaccine 
limitations, lower efficacy in older adults and antigenic differences between vaccine and 
circulating strains, other interventions, such as antivirals, may need to be considered 
(Szucs, 1999). 
Influenza infections have a substantial economic impact (Karve et al., 2013; 
Szucs, 1999). Cost analyses of influenza burden and the impact of its interventions aid in 
policy decisions (Ott et al., 2013; Peasah et al., 2013). High income, temperate-climate 
countries have provided the majority of currently available cost evaluations (Ott et al., 
2013; Peasah et al., 2013). A few publications on cost analysis come from middle income 
countries (Ott et al., 2013; Peasah et al., 2013). Evaluations in lower middle income and 
low income countries are lacking (Ott et al., 2013; Peasah et al., 2013). Since cost 
analyses are lacking despite the evidence of substantial influenza disease burden, middle 
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and low income countries do not have sufficient evidence to support the establishment of 
influenza vaccine policies or recommendations (Ott et al., 2013; Peasah et al., 2013) 
(Samaan et al., 2013).                    
 
Applications of influenza burden estimates 
Burden estimates provide evidence of disease and improve the understanding of 
influenza epidemiology. Prior to the expansion of surveillance and laboratory capacity, 
many developing countries were unaware of the impact of influenza (Katz et al., 2012; 
Muyembe Tamfum et al., 2012; Nyatanyi et al., 2012; Schoub, 2010; Steffen et al., 
2012). Influenza, in fact, may have been misdiagnosed as malaria or as other diseases 
with nonspecific symptoms (Muyembe Tamfum et al., 2012; Schoub, 2010). Using 
laboratory diagnostics has confirmed the presence of influenza in circulation and as a 
cause of morbidity and mortality for all ages worldwide (Layne, 2006; Nyatanyi et al., 
2012; WHO, 2011b).  
One key aspect of influenza epidemiology is seasonality and timing of virus 
circulation each year. A peak of influenza confirmed cases may occur during the same 
time period for multiple years in a particular region or country (L. Simonsen et al., 1997). 
Studying this trend or occurrence may reveal the seasonality of influenza disease (L. 
Simonsen et al., 1997). Knowing when influenza occurs allows leaders to plan and 
implement control and prevention measures, and to potentially evaluate those measures 
over time (Muyembe Tamfum et al., 2012) 
In addition to detection, some laboratory diagnostics permit further characterization 
of strains, such as the identification of virus types and/or subtypes (Layne, 2006). The 
coordinating centers for the World Health Organization (WHO) rely on such work to 
evaluate strain variability and to inform their recommendations for the annual vaccine 
strain selection (CDC, 2012; WHO, 2014c). To ensure coverage of vaccine strains, it is 
essential to have good, reliable global surveillance (Layne, 2006; Schoub, 2010). Not all 
countries have the capacity to implement and maintain influenza surveillance systems 
(Schoub, 2010). In developing countries, surveillance systems often depend on additional 
financial support from donors (Layne, 2006; Lutwama et al., 2012). Evidence provided 
by burden estimates may draw attention to the public health needs for controlling and 
preventing influenza and advocate for further country and donor support (Gordis, 2009). 
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 Beyond routine surveillance for seasonal influenza viruses, increased surveillance 
efforts support detection of novel influenza viruses with pandemic potential (Ayele et al., 
2012; Monto, 2004; Radin et al., 2012). During pandemics, burden estimates are 
generally high, and in many regions of the world too high, to supply the necessary care in 
both treating ill individuals and protecting healthy individuals within the population 
(Ayele et al., 2012; WHO, 2009). Early detection of pandemic viruses through global 
surveillance may lessen the impact if countries are prepared and equipped to recognize 
and manage disease (Layne, 2006; WHO, 2009). Countries with limited resources and 
competing priorities are often forced to rebuild capacity (Lutwama et al., 2012). Global 
estimates of seasonal influenza may provide evidence to support the need to sustain that 
testing capacity.  
In addition to observing seasonal trends of influenza and the high burden of disease 
during pandemics, epidemiologists may also observe an increased number of influenza-
associated hospitalizations and deaths among certain individuals in the population. By 
identifying the individuals at risk, those who experience the greatest burden of influenza 
disease, countries can create targeted campaigns (Azziz-Baumgartner et al., 2013; Dena 
L. Schanzer et al., 2008a). While countries, such as Canada, have observed reductions in 
influenza-associated mortality and morbidity after the implementation of a universal 
immunization program, other countries with limited resources may be able to provide 
similar reductions in disease through targeted campaigns that allow prioritization and 
effective allocation of resources (Fuller et al., 2013; Kwong et al., 2008; Monto, 2004). 
Once these campaigns are implemented, recalculated burden estimates may be used to 
confirm the effectiveness and drive future improvement.  
Through the examination of burden estimates on a global scale, epidemiologists can 
compare and evaluate the effectiveness of interventions against influenza in different 
settings, among diverse populations, and in relation to other pathogens. Even though 
vaccination is considered the only effective means of preventing influenza infections, 
introducing the vaccine may not be cost-effective in certain settings, particularly when 
disease burdens are greater for other pathogens and resources are limited (CDC, 2010, 
2012, 2013; Fiore et al., 2009; WHO, 2005). Over time, this may change, especially if 
disease burdens for influenza and related infections increase (WHO, 2005). In 
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populations with a high prevalence of human immunodeficiency virus (HIV), severe 
outcomes as a result of influenza infections are four to eight times as likely (C. Cohen et 
al., 2012; Gessner et al., 2013; Gessner et al., 2011). The severity of influenza infections 
in HIV patients appears to decline when patients receive antiretroviral therapy along with 
the influenza vaccine (C. Cohen et al., 2012). As individuals recover from influenza 
infections, they may become susceptible to secondary infections (Shrestha et al., 2013). 
Shrestha et al have shown that influenza infections increase a patient’s susceptibility to 
pneumococcal pneumonia by approximately 100-fold (Shrestha et al., 2013). Vaccines 
and other interventions against influenza may assist in reducing the morbidity and 
mortality associated with other pathogens (Shrestha et al., 2013). However, the 
interaction between influenza and other pathogens is complex.  In one hospital setting in 
the US where influenza vaccine coverage is high (78%), researchers observed an increase 
in hospitalizations due to other circulating respiratory viruses in adults ≥ 65 years old 
(Widmer et al., 2012). 
Despite interventions such as vaccines, burden estimates may remain high. To 
uncover the reasons why, further research is needed to monitor trends and severity in 
disease, and to develop new ways to control and prevent disease. Country leaders and 
health planners rely on burden estimates to prioritize investments in health and research 
(Chadha et al., 2013; W. W. Thompson et al., 2009; Yu et al., 2014). Developing 
vaccines that target conserved regions of the influenza virus may lead to broad protection 
and a universal vaccine (Schotsaert & Garcia-Sastre, 2014). Diagnostics with high 
sensitivity and specificity for the influenza could lead to the reduction of nosocomial 
infections and the unnecessary use of antibiotics (W. P. Glezen et al., 1982; Widmer et 
al., 2012). Leaders may also use burden estimates to guide policy and medical practice, 
such as the use of antivirals in hospitalized patients, which have shown to increase the 
chances of survival, and the development of a standardized influenza case definition to 
improve identification and treatment (Jain et al., 2009; Kyncl et al., 2005; Mytton, Rutter, 
& Donaldson, 2012).   
With the recent expansion of sentinel surveillance for influenza infections in 
healthcare facilities of developing countries, more data for influenza-associated 
hospitalizations is available and not yet summarized. A summary of this data as it 
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pertains to the adults provides the needed evidence to inform and guide the global public 
health community in discussions of polices and interventions targeted at influenza-
associated hospitalizations. 
 
 
 
 
 27 
 
Chapter III 
Methods and Procedures 
 
3.1 Data Sources 
 
We derived our study data from two sources: a systematic review of the published 
literature of influenza in hospitalized adults and unpublished data from a working group 
of partners conducting influenza surveillance among hospitalized adults.  
 
Systematic Literature Search 
 
To identify eligible articles, we searched Pubmed, Embase, Web of Science, Global 
Health, LILACS, IndMed, CINAHL, WHOLIS, and CNKI using the following search 
terms and respiratory illness keywords:  “Influenza” or “viral etiology;” respiratory (tract) 
infection/disease/illness; pneumonia, bronchiolitis, bronchitis, “influenza-like illness:” and 
case definitions for ILI (influenza-like illness), SARI (severe acute respiratory illness), 
ARI (acute respiratory illness), ARLI (acute respiratory like illness), LRTI (lower 
respiratory tract illness), or CAP (community acquired pneumonia). We conducted our 
search on all databases simultaneously, over one week. We limited our search to articles 
published between January 1, 1996 and June 30, 2012. Our search was not restricted by 
language or location. We relied on multilingual professionals who either worked in the 
Influenza Division (CDC) or had basic knowledge of influenza and epidemiology to assist 
in the screening and abstracting of data from non-English papers. Additional papers, 
outside of the citation search, were identified from the bibliographies of eligible articles. 
 
Supplemental Unpublished Data 
 
In addition to the systemic review of published literature, we invited international 
collaborators who complete year-round influenza testing of hospitalized adults to 
participate in the study. Together these collaborators cover most if not all WHO regions 
and different World Bank income levels. Some collaborators have participated in the
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SARI, severe acute respiratory infection, network, and have collected influenza testing 
for both pediatric and adult populations.  
  
 
3.2 Data collection 
 
Published Data 
 
After identifying potentially eligible publications in our search, we followed a multi-
step process for collecting data. We first reviewed the titles and abstracts from the list of 
citations captured by our search strategy. We eliminated any review articles or articles 
unrelated to the influenza virus. We continued to screen the articles deemed eligible by 
our citation review.  
In our screening, we utilized a standard set of inclusion criteria (summarized in box 
1). These criteria were defined prior to project implementation and based on previous 
research (Nair et al., 2011; Lafond et al., 2014; Gessner et al., 2011; Simmerman & 
Uyeki, 2008). The purpose of the criteria was to identify comparable data sources that 
provided the percent of adult inpatients that tested positive for influenza viruses (our 
primary outcome), and compare the effects of factors such as  year, age group, location, 
case definition, or influenza diagnostic tool on the positive influenza-tested percentage 
(secondary outcomes). Article must provide total number tested for influenza and among 
those tested the total number of influenza positive for adult inpatients. Articles must have 
data for inpatients. We defined inpatients as patients admitted into the hospital. 
Emergency room department admissions were considered outpatients unless later 
specified that patients required hospitalization. Studies collected data for adults only or 
reported by age group. Individuals 18 years or older were considered adults if not 
otherwise noted. To ensure that we included a dataset only once, original research was 
required. Authors either collected and used data or were the only ones to use data for 
investigating positive influenza inpatients. Since we are interested in the circulation of 
influenza among the general population, healthcare-acquired influenza infections were 
excluded. The circulation of influenza tends to be seasonal in most regions. To control for 
this seasonality, studies completed at least 12 months of continuous influenza testing.  
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We required laboratory confirmation of influenza for ensuring accuracy of our primary 
outcome. Inpatients may present onset and symptoms similar to influenza but do not have 
an influenza infection according to laboratory test. In light of diagnostic differences in 
sensitivity and specificity, studies listed the influenza confirmation test. Studies tested a 
minimum of fifty inpatients for influenza, in attempts to maintain adequate power for 
estimation and limit type I errors.  
Box 1. Inclusion Criteria  
1. Adult inpatient data 
2. Original research  
3. Community-acquired influenza 
4. 12 months of continuous influenza testing  
5. Laboratory confirmation of influenza  
6. Diagnostic test description 
7. Total number tested for influenza   
8. Total number of influenza positive for adult inpatients  
9. Minimum of fifty inpatients for influenza  
 
Once we confirmed that screened article matched the criteria, we abstracted and 
recorded the outcome measurements and related factors (listed in box 2). 
Box 2. Recorded Outcome Measurements 
1. Positive percentage of influenza 
 What is the total of patients tested for influenza? 
 Of this total, how many are positive for influenza, positive for influenza type A 
and/or influenza type B? 
2. Year 
 When did the study occur? What are start and end dates? 
 Was the study completed during a pandemic or seasonal influenza season? 
3. Adult age range 
 What is the age range of the adult inpatients tested for influenza? 
 If influenza testing results were given by age group, what is the total tested and total 
positive for the following age groups: 18-45, 45-64, and ≥65? 
4. Location 
 Where did the studies and testing occur, where were the patients enrolled (city or 
town, and country)? 
 Which WHO region did the study’s or working group collaborator’s country belong 
to? 
 According to the World Bank income standards, would this country be described as 
high, middle-high, middle-low, or low income? 
 Also, would this country during the testing timeframe be described as industrial or 
undeveloped? 
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Box 2. Recorded Outcome Measurements 
5. Case definition 
 What guidelines are used to direct hospital admission and laboratory testing? 
 How do authors/work group collaborators define influenza disease in their 
studies/populations? 
6. Influenza diagnostic tool 
 What laboratory test was used to confirm suspected cases? 
 What type of specimen was collected and tested? 
 
 Two or more reviewers completed each step, ensuring that articles were at least 
doubly reviewed and screened, and that data was doubly abstracted. Any discrepancies 
between reviewers were discussed. If discussion did resolve discrepancies, reviewers 
were asked to re-screen and abstract data. Data collection tools were piloted, tested and 
results evaluated by reviewers, prior to implementation and for training purposes. We 
found that piloting the collection tools allowed us to ensure that approach by all 
reviewers was consistent, utilizing the same definitions, and to confirm that our tools 
captured our outcomes of interest. We also completed a bias assessment, study and 
outcome level on the eligible articles (box 3). 
Box 3. Bias Assessment  
Yes = (score) 
1. Selection 
i. Was a standard criteria, such as a case definition, used in selecting inpatients   
      for influenza testing? (1) 
ii. Was the method for selecting inpatients for influenza testing unclear or  
      undefined?   (0) 
2. Comparability 
i. Within the case definition, does the article describe or list symptoms or signs?  
     (1) 
ii. Does the article list a syndrome (such as LRTI or community-acquired  
     pneumonia) without describing symptoms (0)? 
3. Outcome 
a. Reporting 
i. Do the authors clearly provide total number of inpatients tested for influenza  
            and of those tested, the number of inpatients who were positive for influenza?  
            (1) 
   ii. Do authors not clearly provide the total influenza tested and the total positive   
       for influenza? (0) 
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Unpublished Data 
 
We used a template for collecting standard outcome data from working group 
participants. Participants provided a basic description of their surveillance system. This 
basic description includes start year, age group testing, lists of inpatient surveillance sites, 
case definition used and start time of using definition, sampling strategies used for 
influenza testing during influenza and non-influenza seasons, type of sample collected 
and tested, and the diagnostic method used in influenza testing (method, percentage of 
samples used with each method used, and when method was used). The template also 
captured influenza testing by year (start and end date for each testing year, from 2005 to 
2012), age group (18-49, 50-64, 65-74, and 75+), and serotype (pH1N1, H3N2, B, and 
seasonal H1N1). Optionally, participants provided site-level results for influenza-testing 
by age group. No individual patient data was collected. 
  
3.3 Data Management and Analysis 
 
For analysis, we used Stata and SAS version 9.3 software. We divided our datasets 
into seasonal, pre- and post-pandemic, and pandemic timeframes. We defined pandemic 
as datasets with data collected during the 2009 year. Seasonal datasets excluded 2009-
year data. Our analysis excluded datasets that combined seasonal and pandemic 
timeframes. We also used two age groups, 18-64 and 65+, for our analysis. We 
completed descriptive analysis, stratifying by data source (published articles or working 
group submissions), using SAS. We calculated crude median results for outcomes of 
interest—number tested, number of influenza positive, and percent positive—using non-
parametric tests for difference by Kruskal Wallis, rank sum.  
To determine if timeframe influenced our crude proportions, we stratified the datasets 
by timeframe. We observed differences between age groups, data sources, case 
definitions, and income levels with the inclusion of pandemic datasets. Due to this 
observation, we restricted the meta-analysis to seasonal datasets. Using seasonal datasets, 
we generated adjusted pooled estimates and 95% confidence intervals for the proportion 
of specimens testing positive for influenza by key age groups, study population types, 
geographical region, and income and development status. These adjusted pooled 
estimates and confidence intervals were calculated through the use of the log binomial 
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model in SAS, accounting for random effects at the dataset level. When the SAS model 
did not converge or there were insufficient data points, we used the Stata random-effects 
model, DerSimonian-Laird method, for the adjusted pooled estimates and confidence 
intervals. If a seasonal dataset provided data by year, we treated each year of data as a 
single observation in the model and defined datasets as clusters. Due to the known 
varying sensitivity of influenza diagnostic tests, we also stratified the pooled estimates by 
polymerase chain reaction (PCR) testing, the gold standard of influenza laboratory 
confirmation, and compared the stratified estimates to the estimates including all testing 
methods used. 
 
3.4 Exploratory Analysis 
 
We also conducted exploratory analyses on potential impact of bias, calendar year 
2010 data, partial-years data, and multipathogen detection on our crude and pooled 
estimates. For our calculations of estimates, we used rank sum non-parametric tests and 
the SAS binomial log regression model.  
In our exploratory analysis of bias, we defined total bias as the sum of selection, 
comparability, and outcome bias. As mentioned earlier, we completed the bias 
assessment by scoring each published dataset for the three components, using 0 for not 
meeting the criteria or 1 for meeting the criteria. A total bias of 3 was considered the 
highest level of quality, while a total bias of 0 was considered the lowest. We explored 
the impact of article quality on positive proportions. 
Since pandemic H1N1 remained in circulation during 2010, we removed 2010-year 
data and reanalyzed the seasonal datasets. We observed in earlier analysis that the 
inclusion of pandemic datasets showed variation among key variables. To ensure that our 
crude and pooled estimates were reliable and we have accounted the full time period in 
which the pandemic H1N1 influenced our estimates, we calculated and compared the 
crude and pooled estimates of seasonal datasets without 2010-year data to the estimates 
including all seasonal datasets.        
We defined partial-years data as datasets which completed ongoing influenza testing 
beyond a 12-month period, such as 15 and 26 months. Datasets with partial years may 
potentially include multiple peaks of influenza circulation and as a result of this 
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inclusion, inflate our pooled and crude estimates. We stratified datasets by whether they 
contained partial years of data and compared the estimates. 
We considered datasets which tested for other pathogens in addition to influenza type 
A and B as datasets completing multipathogen detection. Other viruses frequently co-
circulate with influenza. These viruses as well as bacteria can co-exist with influenza in 
the human hosts and may increase the severity of the infection. To explore whether 
datasets that tested for other pathogens in addition to influenza were likely to have higher 
or lower crude proportions and pooled estimates, we stratified the published datasets by 
multipathogen testing.         
  
3.5 Human Subjects Considerations  
 
In our study, we used published data and aggregated data from consenting 
collaborators. No individual patient data was collected. Due to the nature of our sources, 
no human subject investigational review was required.  
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Chapter IV Results 
 
4.1 Description of data sources 
 
Figure 1 describes the number of eligible publications for each step in the literature 
review and the number of eligible surveillance datasets included in analysis.  For full 
details of each search and more information about datasets, refer to appendices 1-3.  
Figure 1. Flow diagram of data sources identified for systematic review of influenza testing among 
hospitalized adults (Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA, 
(Moher, Liberati, Tetzlaff, Altman, & The, 2009)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49,603 records identified through 
database searches 
53 additional records identified 
through other sources 
38,032 records after duplicates removed 
38,032 records screened 
37,129 records excluded, not 
relevant to topic 
903 full-text articles assessed for 
eligibility 
855 full-text articles excluded 
782 did not meet inclusion criteria 
25 duplicate datasets 
  
  
77 studies included in 
qualitative synthesis 
68 studies included in 
quantitative synthesis (meta-
analysis) 
29 unpublished surveillance datasets 
identified for inclusion 
48 full-text articles included in 
qualitative synthesis 
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We described the data by source in table 1. Published and unpublished datasets 
together covered 31 years, 1981 to 2012. The majority of datasets, whether published or 
unpublished, was one to two years in duration and had a population size of 100 to 500 
individuals. Six published articles and three unpublished datasets only provided 
combined pre-pandemic/pandemic data (data not provided by year) and were excluded 
from analyses, which were split into seasonal and pandemic periods. Between the two 
sources, good global representation was seen for all World Health Organization (WHO) 
regions. China and Spain provided the most datasets (5 each) followed by Thailand (4), 
Australia (3), Germany (3), and Italy (3). All income levels and country developmental 
status, as defined by the World Bank and United Nations Population Division 
respectively, were covered by the two sources. Data sources did differ as we described in 
the following paragraphs. 
By study design, published datasets were heterogeneous. Age ranges varied and 
were often not matched with the number of enrollees. Many datasets described the age of 
their study population as “adult,” ≥14 years of age. Published datasets were older than 
unpublished datasets. Most publications were from the pre-pandemic (pre-2009) 
timeframe. In confirming influenza, published datasets most commonly used polymerase 
chain reaction (PCR) with other diagnostic tests. Some of the other tests may include 
serology, culture, and immunofluorescence. Serology, both single and paired serum, 
followed PCR for testing. These tests were performed on individuals meeting the preset 
case definition. The most common influenza case definition was pneumonia; the case 
definition for severe acute respiratory infection (SARI, (WHO, 2013) was not used in any 
of the published datasets. Published datasets were predominately from the European 
region, and more frequently from high income, industrialized countries. One-fourth of the 
datasets targeted special populations (chronic obstructive pulmonary disease, COPD; 
immunocompromised; ICU patients; and acute asthma patients). Many datasets also 
provided results for pathogens other than influenza, most commonly for respiratory 
syncytial virus (RSV) and parainfluenza. Little information was provided for vaccine 
status. Majority of published datasets provided comorbidity information, although less 
than half of the studies provided severity data, percentage of mortality and ICU 
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admissions among their study populations. From these studies, we calculated a median 
mortality percentage of 7% and median percentage of ICU admissions of 9%.         
Using the influenza surveillance collection form, unpublished datasets captured 
outcome measures by pre-defined age groups (18-49 years, 50-64 years, 65-74years, and 
75+ years). For our analysis, we used two age groups, 18-64 and 65+. The number of 
unpublished datasets increased with time; years with the largest number of unpublished 
datasets were those following the pandemic (particularly 2010 and 2011). Unpublished 
datasets used PCR alone or with other tests as the primary influenza diagnostic test. 
Pneumonia was not used as the case definition. Instead, unpublished datasets most 
frequently identified cases using the severe acute respiratory illness (SARI) definition. 
These datasets provided more data from the Africa, Western Pacific, and Southeast Asia 
regions. The data were more frequently from lower middle income; all surveillance 
datasets were from developing countries. Unpublished datasets were from influenza 
surveillance platforms that did not target special populations, and due to the design of the 
working group data collection form, data was not collected from working group partners 
on comorbidities or vaccine status, or on the detection of pathogens other than influenza 
types A and B.   
 
Table 1. Characteristics of published studies and surveillance data sources about influenza-associated 
respiratory illness among hospitalized adults, 1981-2012 
 48                                         
Published studies n= 
(%) 
29                                         
Unpublished studies n= 
(%) 
Date of studies 1981 to 2010 2003 to 2012 
Age group in years*   
≥14 44(92%) 29(100%) 
18 – 64 5(10%) 26(90%) 
≥65 9(19%) 17(59%) 
Study duration in years   
1–2 38(79%) 13(45%) 
3–4 6(13%) 10(34%) 
5+ 4(8%) 6(21%) 
Timeframe for outcome data   
Pre-2009** 42(87.5%) 6(14%) 
During 2009 ("pandemic") 0% 9(21%) 
Post-2009 0% 26(59%) 
Total cases tested   
50–99 15(31%) 8(28%) 
100–499 31(65%) 10(34%) 
500+ 2(4%) 11(38%) 
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 48                                         
Published studies n= 
(%) 
29                                         
Unpublished studies n= 
(%) 
Diagnostic test   
Polymerase Chain Reaction (PCR) only 9(19%) 11(38%) 
Immunofluorescence only 1(2%) 0% 
Culture only 2(4%) 0% 
Serology only 13(27%) 0% 
Multiple diagnostic tests, incl. PCR 18(38%) 18(62%) 
Multiple diagnostic tests, excl. PCR 5(10%) 0% 
Case definition‡   
Acute Respiratory Infection 4(8%) 1(3%) 
Acute Lower Respiratory Infection 1(2%) 3(10%) 
Pneumonia 29(60%) 0% 
Severe Acute Respiratory Illness 0% 23(79%) 
Other§ 14(29%) 2(7%) 
Study population   
General adult population 36(75%) 29(100%) 
COPD 7(15%) 0% 
Immunocompromised 2(4%) 0% 
Otherǁ 3(6%) 0% 
WHO region   
African 1(2%) 8(28%) 
Americas 5(10%) 5(17%) 
Eastern Mediterranean 2(4%) 1(3%) 
European 25(52%) 2(7%) 
Southeast Asian 2(4%) 6(21%) 
Western Pacific 13(27%) 7(24%) 
World Bank income level¶   
Low Income 1(2%) 9(31%) 
Lower Middle Income 3(6%) 15(52%) 
Upper Middle Income 6(13%) 5(17%) 
High Income 38(79%) 0% 
Development status†   
Developing 13(27%) 29(100%) 
Industrialized 35(73%) 0% 
Comorbidity Data Provided  40(83.3%) 0% 
Influenza Vaccine Status Data Provided 12(25%) 0% 
Multipathogen Detection Data Provided   
Bacteria₮ 38(79%) 0% 
Respiratory syncytial virus 40(83%) 0% 
Parainfluenza 40(83%) 0% 
Adenovirus 35(73%) 0% 
Rhinovirus  24(50%) 0% 
Human metapneumovirus 20(42%) 0% 
Other viruses¥ 31(65%) 0% 
*Age groups include datasets that use subset within the given range, e.g., "≥14 Years" includes datasets of adults 30 years and older, but not those 
restricted to 40 and older. However, each age-based estimate is only included in one grouping. See supplement for a full description of age ranges. 
**Pandemic defined as calendar year 2009. Six published articles and three working group datasets only provided combined pre-pandemic/pandemic 
estimates. 
‡Case definitions as defined per individual study criteria 
§ Includes: acute febrile illness, respiratory infection, acute exacerbation of chronic illness 
ǁ Includes: ICU patients only, acute asthma patients 
¶Obtained from http://siteresources.worldbank.org/DATASTATISTICS/Resources/OGHIST.xls 
†Source:  United Nations Population Division (UNPD), 2012 World Population Prospects Report 
₮ Testing for Bacteria Includes: Streptococcus pneumoniae, Haemophilus Influenzae, Legionella pneumophila, Coxiella burnetti, Mycoplasam 
pneumoniae, Chlamydophila pneumonia, C. psittaci, Pseudomonas spp, Klebsiella, other Enterobacteriaceae spp, Staphylococcus aureus, Pasteurella 
spp, β-haemolytic Streptococcus, and Mycobacterium, Moraxella catarrhalis, Bacillus subtilis, Leptospira 
¥Other viruses include: enterovirus, coronavirus, herpes simplex 
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4.2 Median Crude Influenza-positive Proportions  
 
4.2a. Crude proportions for all (eligible) datasets 
 
In table 2, we provided crude estimates of respiratory samples from hospitalized 
adults testing positive for influenza by a number of key variables, including age range, 
study population type, income level, case definition, diagnostic test, WHO region, 
country development, documented comorbidities, and influenza vaccine status among 
both published and unpublished datasets. All eligible datasets conducted testing for both 
influenza type A and B, and provided data for populations at 14 years of age or older. A 
limited number of datasets used immunofluorescence and culture as their only diagnostic 
tool. Eastern Mediterranean was the least represented WHO region. The most common 
age range for the influenza-tested individuals was between 18 and 64 years of age. The 
median number of tested individuals was larger for unpublished datasets.  The largest 
median number tested for influenza was diagnosed using the acute respiratory infection 
case definition. The immunocompromised population and culture only diagnostic also 
had a large median influenza-tested population, although they both were among the 
lowest median percent influenza-positive proportion. We noted a low median percent 
influenza-positive proportion for industrialized countries and when using pneumonia as 
the case definition. Although not significant by Kruskal-Wallis, the European WHO 
region had the lowest positive proportion when compared to other regions. We observed 
the largest median influenza-positive proportion for the pandemic (2009) timeframe 
followed by datasets which used multiple diagnostics excluding PCR. ICU patients and 
acute asthma patients together, labeled as “other,” had a large median influenza-positive 
proportion. According to Kruskal-Wallis or Wilcoxon rank sum, there were significant 
differences in the median percent influenza-positive by a number of key variables: study 
types (published vs non-published), timeframes (pre- and post- vs during pandemic), and 
UN country developmental statuses.  
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Table 2. Crude proportion of respiratory samples from hospitalized adults testing positive for influenza by 
age group, study design, and population including all datasets*§ 
 No. of 
studies 
(n=) 
Median 
Number (IQR) 
Median Percent Positive (IQR) p-value** 
   Tested Positive  
Age group in years      
≥14 64 258(147, 753) 21(11, 72) 10% (0.06, 0.18) 0.1254 
18 to 64 26 605(285, 1235) 72(33, 356) 14% (0.09, 0.19)  
≥45 27 300(107, 718) 27(9, 92) 10% (0.08, 0.16)  
≥65 23 159(76, 482) 20(7, 55) 11% (0.06, 0.15)  
Type of study      
Unpublished 
surveillance 
26 760(317, 1538) 80(37, 388) 13% (0.08, 0.24) 0.0094 
Published  39 190(107, 283) 14(7, 21) 8% (0.04, 0.17)  
Timeframe for outcome data      
Pre-2009† 47 190(107, 290) 14(7, 22) 8% (0.04, 0.16) 0.0004 
During 2009 
("pandemic") 
9 501(123, 835) 162(52, 187) 23% (0.14, 0.34)  
Post-2009 26 618(218, 1065) 55(27, 151) 12% (0.08, 0.20)  
Diagnostic test      
PCR only 15 510(205,849) 37(21, 81) 14% (0.06, 0.22) 0.2597 
Immunofluorescence 
only 
1 130 9 7%  
Culture only 1 785 11 1%  
Serology Only 10 240(135, 308) 14(4, 22) 6% (0.04, 0.16)  
Multiple diagnostic 
tests, incl. PCR 
33 266(179, 720) 21(9, 110) 9% (0.05, 0.17)  
Multiple diagnostic 
tests, excl. PCR 
5 84(79, 157) 15(6, 20) 20% (0.07, 0.22)  
Case definition      
Acute Respiratory 
Infection 
4 534(262, 1481) 16(10, 205) 6% (0.02, 0.13) 0.0724 
Acute Lower 
Respiratory Infection 
3 
206(107, 
12779) 
37(14, 1324) 13% (0.10, 0.18)  
Pneumonia 24 189(124, 250) 14(7, 20) 7% (0.04, 0.10)  
Severe Acute 
Respiratory Illness 
21 720(317, 1457) 80(52, 211) 13% (0.08, 0.26)  
Other 13 198(90, 510) 20(7, 37) 16% (0.06, 0.22)  
Study population      
General adult 
population 
54 296(193, 800) 29(13, 80) 10% (0.06, 0.18) 0.1680 
COPD 6 98(85, 148) 12(3, 22) 12%(0.02, 0.22)  
Immunocompromised 2 457(128, 785) 7(2, 11) 1% (0.01, 0.02)  
Other 3 107(79, 187) 19(7, 20) 18% (0.04, 0.25)  
WHO region      
African 8 338(217, 632) 23(14, 64) 8% (0.05, 0.14) 0.4600 
Eastern 
Mediterranean 
2 422(124, 720) 112(13, 211) 20% (0.10, 0.29)  
European 22 239(135, 324) 14(7, 34) 8% (0.02, 0.16)  
Americas 8 262(162, 1261) 18(9, 154) 10%(0.05, 0.17)  
Southeast Asian 7 748(199, 2438) 57(7, 558) 10% (0.06, 0.24)  
Western Pacific 18 208(92, 804) 28(19, 72) 14% (0.08, 0.18)  
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 No. of 
studies 
(n=) 
Median 
Number (IQR) 
Median Percent Positive (IQR) p-value** 
   Tested Positive  
World Bank income level      
Low 10 464 (228, 800) 54(29, 80) 12% (0.06, 0.17) 0.0850 
Lower Middle 15 783(268, 1498) 110(14, 468) 14% (0.06, 0.26)  
Upper Middle 8 211(130, 1462) 29(12, 254) 13% (0.08, 0.19)  
High 32 187(107, 283) 14(7, 22) 8% (0.03, 0.14)  
Development Status      
Developing 35 626(205, 1394) 55(15, 211) 13% (0.07, 0.20) 0.0028 
Industrialized 30 198(107, 296) 14(6, 21) 7% (0.02, 0.13)  
Percent Comorbidity‡      
<65% 8 160(121, 258) 11(6, 22) 8% (0.04, 0.10) 0.8279 
≥65% and <100% 6 250(130, 296) 9(6, 16) 7% (0.03, 0.08)  
100% 10 107(85, 148) 15(3, 20) 12% (0.02, 0.22)  
no data 43 359(206, 1065) 37(15, 120) 12% (0.06, 0.19)  
Vaccine Coverage‡      
<40% 5 198(137, 211) 16(4, 26) 8% (0.02, 0.19) 0.7540 
≥40% 5 217(148, 304) 7(5, 29) 8% (0.04, 0.10)  
no data 57 283(130, 800) 21(13, 80) 10% (0.06, 0.18)  
*Six eligible articles provided data for influenza A only, and were excluded from the overall positive analyses 
§These crude estimates include all datasets: pre-pandemic, pandemic, and post-pandemic. 
**Kruskal-Wallis/Wilcoxon rank sum test. 
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. Since data was provided by year in 
the unpublished datasets, three unpublished datasets were included in two timeframes; six unpublished datasets were in all three timeframes.   
‡Data only available in published studies. Fifteen studies provided approximate totals for percent comorbidity and one study for vaccine coverage. These 
were excluded from analysis. Kruskal Wallis or Wilcoxon rank sums of defined groups; excluded no data. 
 
4.2b.Crude positive proportions by year and virus type or subtype 
 
We used boxplots to present the total proportion of positive influenza by year and 
by virus type or subtype in figure 2. Since unpublished datasets were the only source to 
provide data by year and by virus type or subtype, we constructed the boxplots using the 
unpublished datasets. Although unpublished datasets covered 2003 to 2012, we limited 
our analysis to years with more than one dataset. We had one dataset for each of the 
following years: 2003, 2004, 2005, 2006, and 2012. Virus type A was most commonly 
detected during 2007 to 2011. The largest subtype-specific median influenza-positive 
proportion was seen in 2009 for influenza A (H1N1) pandemic virus. Pandemic H1N1 
decreased in 2010, but was still high. In 2011, pandemic H1N1further decreased. Cases 
of seasonal influenza A (H1N1) were the least commonly detected subtype, and were 
only detected in 2009.  Influenza A (H3N2) virus was detected from 2008 through 2011, 
when it had its highest proportion positive among these datasets. Influenza type B cases 
were confirmed and reported throughout the time period (2007 to 2011) with u-shaped 
positive proportion distribution, decreasing in 2009 and increasing in 2010.  
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Figure 2. Boxplot of the proportion of adult respiratory samples testing positive for influenza virus by year 
and virus 
 
 
4.2c. Crude positive proportions by population characteristics 
 
Some publications provided more details about their study populations, such as 
the percentage of study participants with comorbidities and those who have received the 
influenza vaccine within the last twelve months. In table 2 and 3, we observed a slight 
increase in median percent influenza-positive proportions as the percentage of vaccine 
coverage and comorbidities among the study population increases. This increase, 
however, as calculated by Kruskal-Wallis or Wilcoxon rank sums, is not statistically 
significant (p-values >0.05). It is important to note that majority of studies (49 to 65 of 
the 77 studies) lacked comorbidity and vaccine coverage information. Of the 
comorbidities reported, lung disease was the most common.  
 
4.2d. Pandemic and seasonal crude proportions 
 
To determine whether the data from the pandemic period was influencing the 
trends in the median positive proportion by other key variables, we removed data from 
this timeframe from the crude analyses, and observed a decrease in statistical significance 
in median positive proportions for timeframe variable. In table 3, we showed the crude 
estimates with seasonal (pre and post pandemic) data only. After removing the pandemic 
timeframe from analysis, statistical significance diminished for all groupings, except for 
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UN country development status and timeframe. The highest median influenza-positive 
proportion slightly decreased from 23% to 20%. Studies which used multiple diagnostics 
excluding PCR had the highest median positive proportion. This decrease in median 
positive proportion was observed for many variables, such as age group 18-64 (14% all 
datasets to 12% seasonal datasets only) and developing countries (13% all to 10% 
seasonal). By the number of datasets, we noted that most seasonal datasets used either 
SARI or pneumonia as their case definition, tested individuals using multiple tests 
including PCR, and came from the European WHO region, high or lower middle income 
levels, and developing countries. Datasets, which used acute lower respiratory infection 
as the case definition, had the largest median number of individuals tested for influenza 
(1662, median range = 84 to 1662) and the largest median number of individuals with 
positive influenza laboratory results (164, median range = 7 to 164). Datasets which used 
culture or immunofluorescence as their primary diagnostic test had the lowest median 
number of laboratory-confirmed positive influenza cases.    
We also stratified crude proportions by pandemic datasets alone (appendix 4). 
Pandemic datasets were smaller and lacked power. Generally, when pandemic data was 
available for variables, the pandemic crude proportions were larger than seasonal crude 
proportions (12-42%). None of the published datasets in our systematic review focused 
on the pandemic year alone. We observed a slight statistical difference between case 
definitions, acute lower respiratory infection versus severe acute respiratory infection, in 
the pandemic datasets (p-value by Kruskal-Wallis = 0.0404). No other subgroupings were 
statistically differed by Kruskal-Wallis or Wilcoxon rank sum test. 
 
Table 3. Seasonal crude proportions of respiratory samples from hospitalized adults testing positive for 
influenza by age group, study design, and population*§ 
 No. of 
studies 
(n=) 
Median 
Number (IQR) 
Median Percent Positive (IQR) p-value** 
   Tested Positive  
Age group in years      
≥14 61 209(124, 473) 19(9, 46) 10% (0.05, 0.15) 0.3099 
18 to 64 25 199(112, 528) 22(12, 75) 12% (0.06, 0.16)  
≥45 26 176(86, 558) 18(7, 74) 10% (0.07, 0.14)  
≥65 20 149(88, 441) 16(7, 50) 10% (0.06, 0.15)  
Type of study      
Unpublished 
surveillance 
25 232(136, 805) 26(13, 109) 11% (0.06, 0.15) 0.2124 
Published  39 190(107, 283) 14(7, 21) 8% (0.04, 0.17)  
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 No. of 
studies 
(n=) 
Median 
Number (IQR) 
Median Percent Positive (IQR) p-value** 
   Tested Positive  
Diagnostic test      
PCR only  164(117, 401) 20(13, 36) 13% (0.07, 0.17) 0.1486 
Immunofluorescence 
only 
15 130 9 7%  
Culture only 1 785 11 1%  
Serology Only 10 240(135, 308) 14(4, 22) 6% (0.02, 0.16)  
Multiple diagnostic 
tests, incl. PCR 
32 229(136, 551) 19(8, 70) 8% (0.04, 0.13)  
Multiple diagnostic 
tests, excl. PCR 
5 84(79, 157) 15(6, 20) 20% (0.07, 0.22)  
Case definition      
Acute Respiratory 
Infection 
4 566(283, 785) 21(11, 99) 9% (0.03, 0.13) 0.3623 
Acute Lower 
Respiratory Infection 
3 
1662(826, 
2019) 
164(40, 237) 
13% (0.09, 0.14) 
 
 
              Pneumonia 24 189(124, 250) 14(7, 20) 7% (0.04, 0.10)  
Severe Acute 
Respiratory Illness 
20 192(117, 401) 17(9, 41) 10% (0.06, 0.15)  
Other 14 198(90, 510) 20(7, 36) 16% (0.04, 0.22)  
Study population      
General adult 
population 
53 228(135, 510) 19(9, 52) 10% (0.06, 0.15) 0.1505 
COPD 6 98(85, 148) 12(3, 22) 12%(0.02, 0.22)  
Immunocompromised 2 457(128, 785) 7(2, 11) 1% (0.01, 0.02)  
Other 3 107(79, 187) 19(7, 20) 18% (0.04, 0.25)  
WHO region      
African 8 177(111, 233) 14(8, 27) 8% (0.06, 0.14) 0.9136 
Eastern 
Mediterranean 
1 124 13 10%   
European 22 198(123, 250) 14(8, 25) 8% (0.03, 0.15)  
Americas 8 233(133, 437) 18(9, 46) 10%(0.05, 0.14)  
Southeast Asian 
7 
1130(143, 
1680) 
85(16, 236) 12% (0.06, 0.17)  
Western Pacific 18 203(109, 401) 22(6, 30) 10% (0.05, 0.18)  
World Bank income level      
Low 10 184 (92, 358) 16(13, 28) 10% (0.06, 0.15) 0.4555 
Lower Middle 14 250(140, 955) 26(8, 115) 10% (0.04, 0.16)  
Upper Middle 8 566(130, 1462) 68(15, 120) 12% (0.08, 0.17)  
High 32 187(107, 283) 14(7, 22) 8% (0.03, 0.14)  
Development Status      
Developing 34 208(123, 800) 24(13, 84) 10% (0.06, 0.16) 0.0492 
Industrialized 30 198(107, 296) 14(6, 21) 7% (0.02, 0.13)  
Percent Comorbidity‡      
<65% 8 160(122, 258) 11(6, 22) 8% (0.04, 0.10) 0.8279 
≥65% and <100% 6 250(130, 296) 9(6, 16) 7% (0.03, 0.08)  
100% 10 107(85, 148) 15(3, 20) 12% (0.02, 0.22)  
no data 42 231(136, 582) 21(13, 81) 10% (0.06, 0.16)  
Vaccine Coverage‡      
<40% 5 198(137, 211) 16(4, 26) 8% (0.02, 0.19) 0.7540 
≥40% 5 217(148, 304) 7(5, 29) 8% (0.04, 0.10)  
no data 56 208(117, 536) 19(9, 41) 10% (0.06, 0.15)  
*Six eligible articles provided data for influenza A only, and were excluded from the overall positive analyses 
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§These crude estimates include all datasets: pre-pandemic, pandemic, and post-pandemic. 
**Kruskal-Wallis/Wilcoxon rank sum test. 
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. Since data was provided by year in 
the unpublished datasets, three unpublished datasets were included in two timeframes; six unpublished datasets were in all three timeframes.   
‡Data only available in published studies. Fifteen studies provided approximate totals for percent comorbidity and one study for vaccine coverage. These 
were excluded from analysis. Kruskal Wallis or Wilcoxon rank sums of defined groups; excluded no data. 
 
4.3 Pooled estimates of adult influenza respiratory hospitalizations 
 
Using the binomial regression model in SAS, we calculated pooled estimates for 
the positive proportion of adult influenza hospitalizations by age range, study population 
type, country developmental status, WHO region, and country income level (table 4). We 
included sample size and 95% CI.  Due to statistical, significant differences observed in 
key variables when including pandemic datasets, we used only seasonal datasets in our 
pooled estimate calculations. We calculated an overall pooled estimate of 11% (95% CI, 
0.09-0.12). Pooled estimates ranged from 7% to 16%. Whether restricting analysis to 
PCR only or including all tests, we calculated similar median positive pooled estimates 
for both overall and stratified estimates. We observed very little change in median 
influenza-positive crude proportions and median positive pooled estimates for age 
groups. We noted consistent results, across stratified estimates, for country 
developmental status and country income level. Lower income countries, where PCR was 
used exclusively, had a higher median positive pooled estimate than higher income 
countries. Developing countries had a higher (11-12%) median positive pooled estimate 
than industrialized countries (8%). 
 
 
Table 4: Pooled estimates of global adult influenza-associated hospitalizations, by age group, study 
population, income level and WHO region 
 PCR 
Tested N* 
PCR tested Pooled % 
Positive (95% CI) 
N† 
Pooled % Positive 
(95% CI)† 
Age group in years     
≥14 62 11% (0.09, 0.13) 88 11% (0.09, 0.12) 
18 to 64 44 12% (0.09, 0.15) 50 12%(0.10, 0.15) 
≥45 33 10% (0.09, 0.11) 41 10% (0.09, 0.11) 
≥65 23 10% (0.10, 0.10) 31 10% (0.10, 0.10) 
Study population     
General adult 
population 
59 11% (0.09, 0.13) 80 11% (0.09, 0.13) 
Special population** 5 9% (0.03, 0.30) 9 7% (0.03, 0.16) 
WHO region     
African 14 9% (0.07, 0.12) 15 9% (0.07, 0.12) 
Americas 3 9% (0.03, 0.23) 12 11% (0.08, 0.15) 
Eastern Mediterranean 
  
one 
dataset‡ 
 
European 12 16% (0.08, 0.34) 24 10% (0.06, 0.18) 
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 PCR 
Tested N* 
PCR tested Pooled % 
Positive (95% CI) 
N† 
Pooled % Positive 
(95% CI)† 
WHO region     
Southeast Asian 14 13% (0.08, 0.19) 14 12% (0.08, 0.19) 
Western Pacific 21 11% (0.08, 0.14) 25 11% (0.08, 0.14) 
Income level     
Low Income 17 13% (0.10, 0.17) 18 13% (0.10, 0.16) 
Lower Middle Income 25 12% (0.08, 0.18) 31 12% (0.09, 0.17) 
Upper Middle Income 7 10% (0.07, 0.16) 10 10% (0.07, 0.14) 
High Income 15 9% (0.06, 0.12) 32 8% (0.06, 0.11) 
Development status†     
Developing 51 11% (0.09, 0.14) 61 12% (0.10, 0.14) 
Industrialized 13 8% (0.06, 0.12) 30 8% (0.05, 0.10) 
*Number of data points included in model, including multiple individual years from a single dataset, when available 
**Includes ICU patients, acute asthma patients, COPD patients, and immunocompromised patients 
†All diagnostic tests included 
‡no PCR data 
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients 
  
4.4. Assessment of the impact of dataset quality on influenza-positive proportions 
 
Exploring the impact of article quality on our outcome of interest, we found no 
significant difference in the median influenza-positive proportions among published 
datasets by total bias score (p-value = 0.9255; appendix 5). In our assessment, we 
evaluated selection, comparability, and outcome bias, giving each dataset a bias score of 
0 (undefined) or 1 (clearly defined). Total bias was the sum of this assessment, with 
larger totals correlating with the higher quality. This assessment was limited to published 
datasets. Thirty-eight percent of published datasets were of high quality with total bias 
score of 3. Slightly more datasets were of medium quality, total bias scores of 2 (43%). A 
small subset of datasets had a total bias score of ≤1 (19%). When we stratified the 
published datasets by PCR testing, we observed a statistical difference in median 
proportion positive by selection bias score (p-value = 0.0394); datasets with high quality 
scores, bias score of 1, had a larger median positive proportion (11% compared to 5% for 
datasets with a selection bias score of 0). The statistical difference seen in selection bias 
after stratifying datasets by PCR testing did not influence the overall bias assessment (p-
value = 0.1866). We also noted a larger median positive proportion for datasets where 
PCR was the primary diagnostic test, and published PCR datasets tended to be of high 
quality with a total bias score of 3 (of 3). After we stratified by timeframe, we noted that 
the pandemic datasets had larger median positive proportions as the total bias score 
increased (14% when total bias score equaled 3 and 5% when total bias score equaled 2). 
Seasonal datasets exhibited little to no change in median positive proportion with varying 
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bias assessment scores (10% positive proportion for datasets with total bias score of 0 or 
1, 7% positive proportion for datasets with total bias score of 2, and 8% positive 
proportion for datasets with total bias of 3).   
 
4.5 Exploratory Analyses 
 
4.5a. Impact of pandemic H1N1in 2010 calendar year 
  
To evaluate the possible influence of other factors on the calculated crude 
proportions and pooled estimates, we conducted several post-hoc exploratory analyses. 
The first factor we evaluated was inclusion of calendar year 2010 data in seasonal 
influenza (non-pandemic) estimates. In our primary analyses, we defined pandemic 
datasets as datasets including the 2009 year. However, as seen in figure 2, pandemic 
H1N1 continued to circulate in 2010. As we previously described in table 3, we observed 
a decrease in statistical differences among key variables when we removed 2009-year 
data. To explore whether 2010-year data influenced crude proportions and/or pooled 
estimates for seasonal influenza, we reanalyzed the seasonal data, excluding data points 
from 2010 and compared these findings to the main results (appendix 6). When reviewing 
the datasets without 2010-year data, we observed slight decreases in crude proportions 
(1-20%; examples include 6% without 2010 vs 9% in seasonal for acute respiratory 
infection case definition). The ≥65 age group crude proportions increased after removal 
of 2010 data (10% to 11%). No statistical significance was noted among the crude 
proportions by Kruskal-Wallis or Wilcoxon rank sums in the datasets without 2010-year 
data. Pooled estimates were similar prior to and after stratification, typically 1% to 3% 
lower after 2010-year data was removed. Highest pooled estimate, before and after 
stratification, was for datasets from the European WHO region which used PCR as the 
primary diagnostic test (16%).       
 
4.5b. Potential impact of testing timeframe and detection of other pathogens 
 
4.5bi. Partial year influenza testing stratification  
 
In this study, some datasets collected data for one or more full 12-month periods, 
while others had a time frame of data collection exceeding a multiple of 12 months of 
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ongoing influenza testing (such as 18 or 30 months). We referred to these datasets as 
datasets with partial years of influenza data (appendix 7). To ensure that the datasets with 
partial years did not inflate our pooled and crude estimates due to their potential inclusion 
of multiple peaks of influenza circulation, we stratified the datasets by whether they 
contained partial years of data and compared the estimates. After stratifying the datasets, 
we noticed that there were less datasets with partial-year data than with data completed 
during 12-month periods (36 partial-year datasets had data for the ≥14 year-old age 
group, while 73 full-year datasets included data for the same age group variable, for an 
example). A few variables were specific to datasets with or without partial years. 
Datasets that used immunofluorescence as the only diagnostic test or were from the 
Eastern Mediterranean WHO region completed influenza testing ongoing beyond a 
multiple of 12 months; using culture only or multiple diagnostic testing excluding PCR 
were only seen in datasets without partial-year data.  
Overall, datasets with partial years had similar positive crude proportions, 0-19%, 
compared to datasets without partial years, 0-20%. The multiple tests excluding PCR 
variables remained the largest crude proportions in the datasets without partial years 
(20%). The PCR only datasets with partial-year data had a crude proportion of 19%. This 
crude proportion decreased by 8% when datasets with partial-year data were excluded 
and by 6% when analyzing all eligible seasonal datasets. We noted similar levels of 
decrease in crude proportions after removing partial-year datasets for COPD study 
population (16% partial-year to 8% full-year), Western Pacific WHO region (17% 
partial-year to 9% full-year), and industrialized countries (10% partial-year to 5% full-
year). Increases in crude proportions were observed in datasets without partial-year data. 
Datasets from the Americas WHO region increased 5% after the removal of datasets with 
partial-year data.       
As calculated by Kruskal-Wallis or Wilcoxon rank sums, we observed statistical 
differences for case definition in partial-year datasets (p-value = 0.032). We noted more 
statistical differences for crude proportions in datasets without partial years (pre- and 
post-pandemic timeframe, p-value = 0.038; and development status, p-value = 0.0464).   
When we evaluated the pooled estimates by partial year stratification, datasets 
with partial years versus datasets with full years, we observed little difference in 
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estimates between partial and full year datasets including all diagnostic tests (9-20% and 
4-21% respectively). Pooled estimates for special populations decreased when we 
removed partial-year datasets (20% partial-year to 4% full-year datasets). We also 
noticed a decrease in pooled estimates for datasets from the Southeast Asian WHO region 
after the removal of partial-year datasets (17% partial-year to 11% full-year). European 
WHO region datasets increased from 11% with partial-year datasets to 21% without 
partial-year datasets.       
 
4.5bii. Multipathogen Detection 
 
Other viruses frequently co-circulate with influenza. These viruses as well as 
bacteria can co-exist with influenza in the human hosts and may increase the severity of 
the infection. To explore whether datasets that tested for other pathogens in addition to 
influenza were likely to have higher or lower crude proportions and pooled estimates, we 
stratified the published datasets by multipathogen testing (appendix 8). Only one 
published, seasonal dataset did not test for other pathogens in addition to influenza type 
A and B. Comparing the crude and pooled estimates from the multipathogen testing 
datasets, published only, to those in the seasonal datasets, published and unpublished, we 
noted little change in the estimates (0-6% difference seen among the key variables). The 
overall pooled estimate for the multipathogen testing datasets was 8% (compared to the 
seasonal, 11%). Similar to the seasonal datasets, developing countries had higher pooled 
estimates than industrialized countries (12% vs 7%) in the multipathogen testing datasets. 
We were unable to calculate pooled estimates for three of the six WHO regions (African, 
Eastern Mediterranean, and Southeast Asia), and for low and lower middle income levels 
using the multipathogen testing datasets. With the seasonal datasets, we calculated pooled 
estimates for all variables of interest; we included data from lower income countries and 
all WHO regions in our analysis by supplementing the literature review with surveillance 
data. No statistical significance was observed in the crude proportions for the 
multipathogen testing datasets. 
 To evaluate whether testing for a specific pathogen in addition to influenza 
influenced the influenza-positive crude proportions and/or total tested for influenza, we 
stratified the crude proportions in the multipathogen testing datasets by other pathogen 
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testing. We found that influenza-positive crude proportions increased when excluding 
datasets that tested for RSV, adenovirus, or bacteria (8% prior to stratification; 11% 
without RSV, 22% without adenovirus, and 14% without bacteria). The crude proportions 
further increased when we restricted the analysis to PCR data (17% without bacteria, for 
example). We observed larger median totals tested for influenza when we excluded 
datasets that tested for RSV; parainfluenza; bacteria; or enterovirus, coronavirus, and 
herpes simplex. Totals increased when we included datasets that tested for adenovirus or 
rhinovirus.  
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Chapter V Discussion 
 
5.1 Summary of findings 
 
By combining findings from the published literature with additional unpublished 
surveillance data, we obtained influenza testing results from 50 countries with varying 
income levels, country development status, vaccine policies, and health-seeking 
behaviors over a 31-year period of time. We estimated that 11% (95% CI, 0.09 – 0.12) of 
global adult respiratory hospitalizations were associated with seasonal (non-pandemic) 
influenza. This pooled estimate increased as country income level decreased and as 
country development status decreased (8% (0.06, 0.11) for high income, 10% (0.07, 0.14) 
for upper middle income, 12% (0.09, 0.17) for lower middle income, and 13% (0.10, 
0.14) for low income; 8% (0.05, 0.10) for industrialized countries and 12% (0.10, 0.14) 
for developing countries). The crude (median) proportions were influenced by the 
pandemic time period, with the largest proportion positive (23% IQR 0.14-0.34) occurred 
during 2009. The crude proportion positive for influenza during non-pandemic periods 
was not statistically different by age group, data source, case definition, or country 
income level. 
 
5.2 Evaluation of potential impact on estimates by key variables or with inclusion of  
      pandemic virus  
 
Impact of country income level and development status 
 
Country income and development status had an inverse relationship with the 
influenza-positive pooled estimate and seasonal crude proportions, with increasing 
prevalence of influenza as country income decreased. Comparing the datasets by country 
development status, we notice that majority of datasets provided by developing countries 
were unpublished, used PCR as their main diagnostic test, and were collected post 2009 
pandemic. Timeframe at which specimens were collected and analyzed may influence the 
positive-influenza proportion. At times of heightened awareness of influenza, enrollment 
increases (Ayele et al., 2012). Perhaps, more individuals with influenza seek care and 
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tested positive for influenza after than before 2009. Prior to 2009, influenza data from 
developing, low-income countries was limited, as seen with our meta-analysis and others 
(Briand, Mounts, & Chamberland, 2011; Gessner et al., 2011; Peasah et al., 2013; Savy et 
al., 2013; Simmerman & Uyeki, 2008). With the later time period of testing, developing 
countries were able to use more sensitive methods such as PCR (Das, Spackman, Pantin-
Jackwood, & Suarez, 2009; Kumar & Henrickson, 2012; Pasick, 2008; WHO, 2011a). 
Industrialized countries included our meta-analysis used other tests 
(immunofluorescence, cell culture, and immunoassays), which may have lower 
sensitivity or require advanced technical skill, in addition to PCR (Harper et al., 2009; 
Kumar & Henrickson, 2012). Depending on the testing algorithm and interpretation of 
results, some influenza cases may have been missed (Harper et al., 2009; Kumar & 
Henrickson, 2012).     
While industrialized countries have well-established influenza vaccination programs, 
high vaccine coverage (≥60% among adults ≥65 years old), and in many cases stockpiles 
of vaccines available, developing countries, low and middle income countries struggle to 
have influenza vaccine recommendations or policies established (Mereckiene et al., 2010; 
MIV, 2005; Oshitani, Kamigaki, & Suzuki, 2008; Samaan et al., 2013). During our study 
timeframe, the influenza vaccine available may have provided sufficient protection 
against circulating strains and as result, countries distributing the vaccine to their 
population were able to prevent influenza disease, decreasing the number of individuals 
who tested positive for influenza. Although influenza vaccine effectiveness was reported 
low during the 2003-2004 season in the United States (Herrera et al., 2007), the increased 
vaccine coverage during 2010-2011 and 2012-2013 seasons averted more influenza 
illness and hospitalizations (Bresee et al., 2013; Kostova et al., 2013). 
Differences in host immunity and virulence of influenza may contribute to the 
variation in influenza positive proportions among developing, lower income countries 
and industrialized, high income countries (Freitas et al., 2013; Yang, Chiu, et al., 2011; 
Yu et al., 2014). Influenza disease may lead to more severe outcomes in developing 
countries due to higher prevalence of HIV and malnutrition (Freitas et al., 2013; Tempia 
et al., 2014). Adults infected with HIV are at greater risk of influenza-associated 
hospitalizations (C. Cohen et al., 2012; Gessner et al., 2013). In addition to increased risk 
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of severe influenza disease, immunocompromised adults shed seasonal influenza virus 
detectable by PCR for longer periods of time than immunocompetent adults (Klimov et 
al., 1995; van der Vries et al., 2013; Weinstock, Gubareva, & Zuccotti, 2003). Prolonged 
shedding of pandemic H1N1 virus was detected in both immunocompromised and 
immunocompetent adults (Fleury et al., 2009). The variation of co-circulating viruses and 
bacteria between developing and industrialized countries may also contribute to the 
difference in disease severity (Madhi & Klugman, 2004; Morens, Taubenberger, & Fauci, 
2008). Environmental factors, such as crowded living conditions with close proximity to 
animals, temperature, and humidity, may increase likelihood of influenza transmission 
and/or promote viral survival in developing, lower income countries (Freitas et al., 2013; 
Yang, Chiu, et al., 2011). Sutanto et al observed a decrease in influenza severe outcomes 
when accessibility to health care increased (Sutanto et al., 2002). Developing, low 
income countries often have insufficient number of nurses and doctors on staff, hospital 
beds available, and medical supplies (Oshitani et al., 2008). A low income country with 
large populations, such as Bangladesh, have modest health care infrastructure (Homaira 
et al., 2012). With this lack of access to adequate medical care and modest health 
infrastructures, developing countries experience higher mortality rates due to influenza 
than industrialized countries, according Oshitani and colleagues (Oshitani et al., 2008).  
 
Impact of pandemic H1N1 
 
As we noticed in our analysis, the pandemic H1N1 season was very different from 
other influenza seasons. The largest positive proportions were seen during the pandemic. 
Globally, H1N1 contributed to 201,000 respiratory deaths and 83,300 cardiovascular 
deaths (F. Dawood et al., 2012). When examining the positive proportions by age group, 
we observed slightly higher positive proportions in younger adults, 18-64 years old, than 
older adults, 65 years or older (not statistically significant). This finding is consistent 
with surveillance studies of influenza-associated hospitalizations conducted in the United 
States and India (Chadha et al., 2013; C. M. Cox et al., 2012; N. J. Cox & Subbarao, 
2000). During the pandemic in the United States, influenza-associated hospitalizations 
among younger adults increased 6-folds, in comparison to the average number of 
hospitalizations in this age group during the prior four influenza seasons (C. M. Cox et 
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al., 2012). In India, the highest number of hospitalizations due to pandemic H1N1 was 
among individuals 5-29 years old (Chadha et al., 2013). Although hospitalizations among 
younger adults increased during the pandemic, hospitalizations among adults ≥75 years 
old decreased (C. M. Cox et al., 2012). A large portion of older adults had pre-existing, 
cross-reactive antibodies to pandemic H1N1, according to a serological survey of adult 
serum prior to 2009; these antibodies provided immune protection (Hancock et al., 2009).    
 
Impact of age 
 
After the removal of pandemic H1N1 data (2009 year data), we observed no 
difference in positive proportions by age group (12% (IQR, 0.06-0.16) for 18-64 year 
olds and 10% (IQR, 0.06, 0.15) for 65+). Behbehani et al described this lack of difference 
in their published dataset, when they conducted a year-long study to evaluate the causes 
of community-acquired pneumonia in hospitalized adults in Kuwait (Behbehani et al., 
2005). Earlier studies show that complications, hospitalizations, and deaths due to season 
influenza were greatest among adults ≥65 years of age (CDC, 2010). Due to the higher 
risk for severe outcomes, existing influenza vaccination policies for adults typically target 
this age group (CDC, 2013; Mereckiene et al., 2010; MIV, 2005; WHO, 2012a, 2012b). 
According to recent studies, a large portion of adults ≥65 years old are receiving the 
vaccine (Mereckiene et al., 2010). This increase in vaccine uptake among this age group 
may have prevented disease, if the received vaccine induced an adequate immune 
response in vaccinees against circulating influenza strain(s) (CDC, 2010). Vaccine 
effectiveness, however, is known to be lower in older adults than younger adults due 
dysregulation of the immune system, termed immunosenescence (Reber et al., 2012). 
Older adults may have acquired immunity to circulating strains through prior exposure, 
as seen in the pandemic timeframe (Hancock et al., 2009; Hardelid et al., 2010; Miller et 
al., 2010; Talbot & Falsey, 2010). On the other hand, the datasets included in our study 
may have missed influenza cases in older adults due to atypical presentation, not fitting 
the case definitions, or the inability to collect specimens (Talbot & Falsey, 2010; 
Babcock, Merz, Dubberke, & Fraser, 2008). Influenza often presents without fever in 
older adults and patients with COPD (Talbot & Falsey, 2010). When comparing 
laboratory-confirmed influenza cases, younger adults matched the influenza-like-illness 
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case definitions more frequently than older adults (Babcock et al., 2008; Radin et al., 
2012).  Older adults tend to have less secretions and increased nasal dryness; both of 
which increase the difficulty of collecting specimens and may result in more discomfort 
during the collection process (Talbot & Falsey, 2010). As found from community 
surveys, health-seeking behaviors depend on socioeconomic status, disease severity, and 
age. Children were more likely to be treated than adults in New Mexico, United States 
(D. L. Thompson et al., 2013). During the 2005-2010 influenza seasons in Hong Kong, 
Wang et al observed an increase in excess influenza-related hospitalizations among 
children and young adults and a decrease among adults ≥65 years old (Wang et al., 2012). 
Heighten public awareness of respiratory viruses due to SARS may explain the change in 
health-seeking behavior among parents and young adults (Wang et al., 2012). Older 
adults and adults with underlying conditions usually seek care for influenza-like-
symptoms only after the illness worsens (Biggerstaff et al., 2014). Since influenza illness 
can lead to secondary infections and/or complications of underlying conditions, older 
adults and adults with underlying conditions may go undiagnosed and not tested for 
influenza (Biggerstaff et al., 2014). If even tested for influenza, these patients may not be 
shedding virus at the time of receiving care (Biggerstaff et al., 2014). The differences in 
age distribution among the study populations may also explain the lack of difference 
between the age groups. In developing countries, especially in countries with high 
prevalence of HIV and malnutrition, life expectancy is lower than industrialized countries 
(Gordon et al., 2010; Radin et al., 2012; Takahashi et al., 2013). As a result, the 
population proportion of elderly in Vietnam, for example, is lower than the proportion of 
the population living in the United States (Takahashi et al., 2013). Because our age cut-
offs primarily reflect the unpublished surveillance data, which was collected from 
developing countries only, the older age group may not be well-represented.    
 
Impact of diagnostic tests used 
 
In our analysis, diagnostic test used did not influence the pooled estimates and 
positive proportions. Influenza diagnostic tests have varying sensitivity and specificity 
(Leekha et al., 2013; Sawatwong et al., 2012; Talbot & Falsey, 2010). When respiratory 
specimens are collected soon after onset and stored properly, PCR is considered the most 
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sensitive test, even for adults ≥ 65 years old (Ellis & Curran, 2011; Hopkins, Moorcroft, 
Correia, & Hart, 2011; Leekha et al., 2013; Sawatwong et al., 2012; Talbot & Falsey, 
2010). PCR datasets from a similar meta-analysis of children hospitalized due to 
respiratory infections had higher influenza-positive crude and pooled estimates than non-
PCR datasets (Lafond et al., 2014). In our study, majority of the datasets (100% 
unpublished datasets and 50% published datasets) used PCR alone or with other tests.  
Our analysis may have been limited by the number of datasets not using PCR (56 PCR vs 
21 non-PCR). Of those not using PCR, 86% used paired or single serum serology.  While 
paired serum serology measures fold-rise in antibody titers from initial exposure (vaccine 
or infection) to recovery, single serum serology measures one point in time with pre-
established limits (Broor, Chahar, & Kaushik, 2009; Kumar & Henrickson, 2012).  These 
pre-established limits do not account for pre-existing antibodies due to prior exposure or 
recent vaccination, which may result in false positives (Broor et al., 2009; Kumar & 
Henrickson, 2012). Prior exposure to certain influenza virus types and/or subtypes is 
common in adults, especially older adults (Talbot & Falsey, 2010). We found a 20% 
influenza positive proportion among datasets that used multiple tests excluding PCR in 
our crude analysis; some of these datasets included single serum serology. False positives 
may also result from PCR. Due to its high sensitivity, PCR detects virus in environmental 
contaminants and after the virus no longer replicates (Hopkins et al., 2011; Sawatwong et 
al., 2012). The use of multiple tests may provide a more accurate picture of true 
infections (Sawatwong et al., 2012; Talbot & Falsey, 2010). 
 
Impact of case definition 
 
Case definitions change over time to improve sensitivity and specificity of 
influenza detection. The exclusion of difficulty breathing or shortness of breath, replacing 
the terms with cough, improved the sensitivity and specificity of the SARI case definition 
among hospitalized patients (Gupta et al., 2013; Hirve et al., 2012; Nachtnebel et al., 
2012). Authors who evaluated the pneumonia case definition in three states reminded the 
readers that influenza hospitalizations are associated with other diseases (circulatory, 
neurological, etc.) in addition to pneumonia, and restricting to the use of the pneumonia 
case definition alone may underestimate the burden of influenza hospitalizations (Ortiz et 
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al., 2014). Although case definitions are often subjective and may have differing levels of 
sensitivity and specificity (Nichol & Mendelman, 2004), we did not observe statistically 
significant differences, through non-parametric testing, between case definitions in our 
eligible datasets. 
      
Impact of WHO region 
 
In addition to World Bank and UN development status, WHO region is another 
method of defining a global region (WHO, 2014a). WHO created six regions to ease 
disease reporting and disease data analysis (WHO). Differences in influenza seasonality 
and disease severity have been observed among the WHO regions. The pandemic H1N1 
remained in circulation longer in the Southeastern Asia and African WHO regions than in 
the other four regions, for example (WHO, 2010). Despite differences, we observed no 
statistically significant differences in positive crude proportions for our datasets between 
the WHO regions, implying that WHO regions in our study does not impact positive 
proportions. To improve the estimate for the Eastern Mediterranean WHO region, only 
one dataset was available from this region, more research is needed.         
 
5.3 Limitations and exploratory analysis 
 
Our study is subject to several limitations. Our data were heterogeneous due to 
variability in data sources’ time frames, testing criteria or case definitions, and testing 
procedures. Diagnostic tests also vary in sensitivity and specificity (Leekha et al., 2013; 
Sawatwong et al., 2012; Talbot & Falsey, 2010). As the timing between disease onset and 
specimen collection increases, the ability to detect influenza viruses decreases, especially 
in adults who shed less virus than children (W. P. Glezen, Greenberg, Atmar, Piedra, & 
Couch, 2000; Leekha et al., 2013; Sawatwong et al., 2012; Talbot & Falsey, 2010). 
Further, hospital admission relied on care-seeking behavior and hospital or healthcare 
facility admission policies (Gordis, 2009; Parashar et al., 2003), which may have 
increased or decreased enrollment and did not necessarily influence the percent positive 
for influenza. The severity of influenza may vary by population (Gordis, 2009). We may 
not have accounted for all severe influenza cases, especially in resource-limited areas and 
when patients had non-respiratory presentations of influenza (Freitas et al., 2013; 
57 
 
Oshitani et al., 2008; Radin et al., 2012). We assumed that influenza caused the 
hospitalization and do not account for co-infections and underlying conditions in our 
entire study population. Other viruses, such as respiratory syncytial virus and 
parainfluenza virus, often co-circulate with influenza (Zhou et al., 2012). While all but 
two published datasets tested for other pathogens, we are unaware of whether 
surveillance sites considered other pathogens as the cause of illness. When other 
pathogens in addition to influenza were detected in patients among published datasets, 
the main pathogen contributing to the hospitalization was unknown. Co-infections and 
certain underlying conditions have shown to increase the severity of influenza infections 
(Dena L. Schanzer et al., 2008a). Severity of influenza disease is unknown due to the lack 
of patient outcome data in the majority of study datasets. We may have a reduced 
likelihood of publication bias for influenza results in our findings due to the inclusion of 
published datasets which tested for other pathogens in addition to influenza or found no 
confirmed cases of influenza.  Also, according to the Campbell Collaboration Reviews, 
we may have removed or at least decreased the effect of publication bias by including 
unpublished datasets (C2, 2014). From our quality assessment, 81% of published datasets 
were of median to high quality. To minimize our study limitations, we used a randomized 
effect model and stratified our data by potential factors—the detection of pandemic 
H1N1 during the 2010 calendar year, data collected during multiple influenza seasons, 
and the detection of other pathogens that co-circulate with influenza. 
We found no indication that 2010 calendar year data, partial year data, and multi-
pathogen testing data impacted the overall seasonal pooled estimates (0-19%). Beginning 
in April 2009, public health officials across the globe began to identify pandemic H1N1 
cases (WHO, 2010). The report further described the decreased number of cases due to 
pandemic H1N1 in most countries and the increased rates of cases due to influenza type 
B (WHO, 2010). Our boxplot demonstrated this trend. As we described earlier, the 
inclusion of pandemic data (from calendar year 2009) impacted our crude and pooled 
estimates. While the pandemic virus, continued to circulate after 2009, it did not have the 
same impact in 2010, as seen in our crude and pooled estimates when stratifying seasonal 
results to include or exclude 2010 calendar year data.  
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Datasets with partial year data (e.g., >12 months but <24 months) could have 
potentially over- or under-estimated the proportion of hospitalizations due to influenza if 
they over-represented or under-represented months with peak influenza circulation. 
Although some datasets in our study included partial year data, we did not see this impact 
our global pooled estimates. We also included countries with subtropical and tropical 
climates where influenza occurs year-round (Simmerman & Uyeki, 2008; Cécile Viboud 
et al., 2006). The Southeast Asian WHO region includes some subtropical countries 
(Simmerman & Uyeki, 2008). Even though we found slightly higher crude and pooled 
estimates for this region when including datasets with partial years, we are limited in 
drawing conclusions due to the small number of datasets with partial year data from this 
region and not knowing whether influenza-positive cases increased after the completion 
of the study.  
 
5.5 Closing remarks 
 
In this first attempt to summarize the global burden of severe influenza infection 
among both younger and older adults, we found 11% of cases from adult respiratory 
hospitalizations worldwide were laboratory-confirmed for influenza. This estimate 
indicates that all adults, independent of age and country origin, are affected by influenza. 
For countries without reliable influenza data, we provide an estimate that they may use in 
planning and allocating resources for the control and prevention of influenza in their 
adult populations. From a global health perspective, it is important to understand how to 
use this estimate for health planning and strategy; this will require further discussion. In 
calculating this estimate, we focused on the most recognizable presentation of influenza 
in hospitalized patients, respiratory infections (CDC, 2010; Hirve et al., 2012). Although 
influenza has been identified in patients who are admitted for other reasons (circulatory 
and even all-causes according to the hospital admission forms), these patients are not 
typically tested for influenza due to high costs and labor demands (W. W. Thompson et 
al., 2009). Vaccine status of hospitalized patients and the use of other interventions are 
not often recorded. As more data becomes available, researchers will be able to evaluate 
the effectiveness of influenza vaccines and other interventions on preventing and 
reducing influenza hospitalizations. Since influenza is a mutable virus, the global 
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estimate is likely to vary from year to year, depending on the virus type in circulation and 
the occurrence of a pandemic (CDC, 2013). The interaction between influenza and other 
pathogens is complex and may contribute to severe outcomes (Rothberg, Haessler, & 
Brown, 2008). Evaluating this interaction may provide some insight for preventing such 
outcomes. Currently, annual influenza vaccination is the main method of prevention 
(CDC, 2013; Couch, 2000). The use of a universal vaccine, especially if it provides long-
lasting broad coverage and is effective in adults with aging immune systems, will likely 
lead to reductions in influenza hospitalizations (McElhaney, 2005; Schotsaert & Garcia-
Sastre, 2014). In effort to identify the circulating influenza virus and potentially improve 
the selection of vaccine strains, it is important to continue supporting the increased 
capacity of influenza testing and vaccine production in developing countries (Friede et 
al., 2011; Mmbaga et al., 2012; Partridge & Kieny, 2013). Many developing countries 
cannot afford to vaccinate (Oshitani et al., 2008); efforts to decrease vaccine costs and to 
determine more feasible vaccination approaches for developing countries are needed. 
Whether living in a developing or industrialized country, adults of all ages are affected by 
influenza. Severity of disease varies and the burden of this severity as seen with 
hospitalizations will change with time. With strengthen surveillance systems and the 
continuation of collecting and publishing data, burden estimates will become more 
robust. 
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Appendices 
 
Appendix 1. Literature Search Methodology by Database  
(Web appendix from Lafond et al., 2014) 
 
Pubmed: 3596 results 
1. influenza, human[sh] OR influenza A virus[majr] OR influenza B virus[majr] OR influenza C 
virus[majr] OR influenza[all] OR viral etiology[all] 
2. respiratory tract infections[sh] OR respiratory tract diseases[sh]  
3. pneumonia[majr] OR pneumonia, viral[sh]  
4. bronchiolitis[sh] OR bronchiolitis, viral[sh] OR bronchopneumonia[sh] 
5. influenza-like illness[all]  
6. acute respiratory[all] OR acute lower respiratory[all] OR lower respiratory[all]  
7. ILI[all] OR SARI[all] OR ALRI[all] OR LRTI[all] OR CAP[all] 
8. 1 AND (2 OR 3 OR 4 OR 5 OR 6 OR 7) 
9. Limit 8 to ("1996/01/01"[PDAT] : "3000/12/31"[PDAT]) AND "humans"[MeSH Terms]) 
 
Embase (Ovid): 34349 results 
1. exp influenza/ OR exp influenza virus/ OR exp influenza A/ OR exp influenza B/ OR exp influenza C/ 
OR exp influenza virus A / OR exp influenza virus B / OR exp influenza virus C / OR exp  seasonal 
influenza/ OR influenza.mp OR viral etiology.mp 
2. exp respiratory tract infection/  OR exp acute respiratory tract disease/ 
3. exp pneumonia/ OR  exp virus pneumonia/ 
4. exp bronchiolitis/ OR exp viral bronchiolitis/ OR exp bronchitis/ 
5. exp flu like syndrome/ OR influenza-like illness.mp  
6. ILI.mp OR SARI.mp OR ARI.mp OR ALRI.mp OR LRTI.mp OR CAP.mp 
7. 1 AND (2 OR 3 OR 4 OR 5 OR 6) 
8. Limit 7 to (human and yr=”1996-Current”) 
 
Global Health (Ovid): 4068 results 
1. exp influenza/ OR exp influenza viruses/ OR exp Influenzavirus A/ OR exp Influenzavirus B/ OR exp 
Influenzavirus C/ OR influenza.mp OR viral etiology.mp 
2. exp respiratory diseases/  or exp lower respiratory tract infections 
3. exp pneumonia/  
4. exp bronchiolitis/ OR exp bronchitis/ 
5. influenza-like illness.mp OR ILI.mp OR SARI.mp OR ARI.mp OR ALRI.mp OR LRTI.mp OR 
CAP.mp 
6. 1 AND (2 OR 3 OR 4 OR 5) 
7. Limit  to yr=”1996-Current” 
 
CINAHL via EBSCOhost: 630 results 
(TX influenza OR TX influenza virus OR TX viral etiology) 
AND 
(TX respiratory infections OR TX pneumonia OR TX influenza-like illness OR TX acute respiratory OR 
TX lower respiratory OR TX "ILI" OR TX "SARI" OR TX "ALRI" OR TX "ARI" OR TX "LRTI" OR TX 
"CAP") 
Limiters: 1996-2012; human 
WHOLIS: 10 
(influenza OR influenza virus OR viral etiology)
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CINAHL via EBSCOhost (continued) 
AND 
(respiratory infection OR respiratory disease OR respiratory illness OR acute respiratory OR lower 
respiratory OR pneumonia OR bronchiolitis OR bronchitis OR SARI OR ILI OR ARI OR ALRI OR LRTI 
OR CAP) 
Publication year: 1996-2012 
 
 
Web of Science via Web of Knowledge: (SCI-EXPANDED): 6018 
(TS= (Influenza) OR TS=(viral etiology)) 
AND 
(TS=(Acute Respiratory Infections) OR TS=(respiratory diseases) OR TS=(respiratory illnesses) OR 
TS=(Pneumonia) OR TS=(influenza-like illness) OR TS=(lower respiratory tract infections) OR 
TS=(bronchiolitis) OR TS=(bronchitis)) 
Time span= 1996-2012 
 
LILACS and IndMed: 275, 4 
(Influenza) 
AND 
(respiratory disease OR respiratory infection OR OR pneumonia) 
 
 
CNKI: 883 results 
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 呼吸系统感染 (respiratory infection)   
甲流 or 流感 or 病毒病原学(influenza group keywords )And  呼吸系统疾病 ( another name of respiratory 
infection)  
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 肺炎 or下支气管炎 (pneumonia or 
bronchiolitis ) 
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 肺炎 or 上支气管炎 (pneumonia or 
bronchitis ) 
甲流 or 流感 or 病毒病原学 (influenza group keywords) And  流感病样病例 (ILI Chinesename) or ILI   
甲流 or 流感 or 病毒病原学 (influenza group keywords) And  急性呼吸道感染( sari chinese name) or  
SARI  
甲流 or 流感 or 病毒病原学 (influenza group keywords) And ARI    
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 急性下呼吸道感染 (LRTI Chinese name) 
or LRTI  
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 急性上呼吸道感染 (LRTI Chinese name) 
or LRTI  
甲流 or 流感 or 病毒病原学 (influenza group keywords) And  非典型肺炎 (SARS Chinese name) or 
SARS  
甲流 or 流感 or 病毒病原学 (influenza group keywords) And 社区活动感染 (CAP Chinese name) or 
CAP  
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Appendix 2. Summary of Published Datasets Used in Analyses 
Location Years Study 
Population 
Case Definition Age 
Range 
Diagnostic Test % 
Influenza 
Positive 
≥14 
% 
Influenza 
Positive 
15-64 
% 
Influenza 
Positive 
≥45 
% 
Influenza 
Positive 
≥65 
Total % 
Influenza 
Positive 
Multiple Sites, 
Kuwait1 
2000-2001 general Pneumonia >=18 Enzyme-linked 
Immunosorbent 
Assay (Paired or 
Single serum) 
10.5 - 7.4 - 10.5 
Shatin, Hong 
Kong2 
2004-2005 COPD Acute 
Exacerbations of 
COPD with 
Pneumonia 
Adults Polymerase Chain 
Reaction, Viral 
Culture (Respiratory 
Specimen), and 
Complement Fixation 
(Paired Sera) 
7.6 - - - 7.6 
Noumea, New 
Caledonia3 
2006-2007 general Pneumonia >=18 Polymerase Chain 
Reaction, 
Immunofluorescence 
Assay (Respiratory 
Specimen), and 
Serology (Paired 
Sera) 
19.0 - - - 19.0 
Coast 
Province, 
Kenya4 
1994-1996 general Pneumonia >=18 Complement Fixation 
(Paired Sera) 
6.1 - - - 6.1 
Chiang Mai, 
Thailand5 
2006-2008 general Pneumonia >=18 Polymerase Chain 
Reaction 
5.9 - - - 5.9 
Multiple Sites, 
Thailand6 
2001-2002 general Acute Febrile 
Illness 
>=18 Enzyme-linked 
Immunosorbent 
Assay (Paired Sera) 
-* - - - - 
Santiago, 
Chile7 
2003-2004 general Pneumonia >=18 Immunofluorescence 
Assay 
6.9 - - - 6.9 
Buenos Aires, 
Argentina8 
1998-2001 general Pneumonia >=18 Immunofluorescence 
Assay, Viral Culture 
(Multiple Respiratory 
Specimens), and 
Complement Fixation 
(Sera) 
2.0 - - - 2.0 
Shenzhen, 
China9 
2003-2005 general Pneumonia >=18 Polymerase Chain 
Reaction 
22.8 - - - 22.8 
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Location Years Study 
Population 
Case Definition Age 
Range 
Diagnostic Test % 
Influenza 
Positive 
≥14 
% 
Influenza 
Positive 
15-64 
% 
Influenza 
Positive 
≥45 
% 
Influenza 
Positive 
≥65 
Total % 
Influenza 
Positive 
Dalian, 
China10 
1997-2000 general Pneumonia >=18 Enzyme-linked 
Immunosorbent 
Assay (Blood) 
-* 18.0* 15.0* 14.5* -* 
Shenzhen, 
China11 
2007-2008 general Respiratory 
Infection 
>=18 Polymerase Chain 
Reaction 
17.3 18.2 19.0 15.8 17.3 
Barcelona, 
Spain12 
1991-1995 Immunoco
mpromised 
Acute 
Respiratory 
Infection 
Adults Viral Culture 1.4 - - - 1.4 
Cologne, 
Germany13 
2003-2004 Immunoco
mpromised 
Pneumonia >=18 Polymerase Chain 
Reaction, Viral 
Culture, and Antigen 
Detection 
(Respiratory 
Specimen) 
1.6 - - - 1.6 
Multiple Sites, 
Spain14 
1992-1994 COPD Pneumonia Adults Complement Fixation 
(Paired Sera) 
- - - - - 
Bochum, 
Germany15 
1998-1999 COPD Acute 
Exacerbations of 
COPD 
>=18 Polymerase Chain 
Reaction 
22.4 - - - 22.4 
Beer-Sheva, 
Israel16 
1997-1999 COPD Acute 
Exacerbations of 
COPD 
>=65 Enzyme 
Immunoassay (paired 
sera) 
- - - - 15.8 
Utrecht, 
Netherlands17 
2002-2004 general Lower 
Respiratory 
Infection 
>=18 Polymerase Chain 
Reaction, Viral 
Culture, and 
Immunofluorescence 
Assay (Multiple 
Respiratory 
Specimens) 
13.1 - - - 13.1 
Beer-Sheva, 
Israel18 
1991-1992 general Pneumonia >=18 Complement Fixation 
(Paired Sera) 
5.8 - - - 5.8 
Leiden, 
Netherlands19 
1991-1993 general Pneumonia >=18 Complement Fixation 
(Paired Sera) 
5.9 - - - 5.9 
Barcelona, 
Spain20 
1995-2001 general Pneumonia >=18 Enzyme 
Immunoassay (Paired 
Sera) 
-* - - - - 
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Location Years Study 
Population 
Case Definition Age 
Range 
Diagnostic Test % 
Influenza 
Positive 
≥14 
% 
Influenza 
Positive 
15-64 
% 
Influenza 
Positive 
≥45 
% 
Influenza 
Positive 
≥65 
Total % 
Influenza 
Positive 
Nottingham, 
United 
Kingdom21 
1998-1999 general Pneumonia >=18 Complement Fixation 
(Paired Sera) 
20.8 - - 19.6 20.8 
Province of 
Kuopia, 
Finland22 
1981-1982 general Pneumonia Adults Complement Fixation 
(Paired Sera) 
2.2 6.7 0.9 - 2.2 
Turku, 
Finland23 
1999-2004 general Pneumonia >=18 Polymerase Chain 
Reaction, 
Fluoroimmunoassay 
(Multiple Respiratory 
Specimens), and 
Serology (Paired 
Sera) 
7.8 - - - 7.8 
Alkmaar, 
Netherlands24 
1998-2000 general Pneumonia >=18 Polymerase Chain 
Reaction 
(Respiratory 
Specimen) and 
Enzyme-linked 
Immunosorbent 
Assay (Paired Sera) 
4.5 - - - 4.5 
Leiden, 
Netherlands25 
2000-2002 general Pneumonia >=18 Polymerase Chain 
Reaction (Multiple 
Respiratory 
Specimens) and 
Complement Fixation 
(Paired Sera) 
9.8 - - - 9.8 
Barcelona, 
Spain26 
2003-2004 general Pneumonia >=18 Polymerase Chain 
Reaction, 
Immunofluorescence 
Assay, Viral Culture 
(Respiratory 
Specimen), and 
Complement Fixation 
(Paired Sera) 
 
 
8.1 - - - 8.1 
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Location Years Study 
Population 
Case Definition Age 
Range 
Diagnostic Test % 
Influenza 
Positive 
≥14 
% 
Influenza 
Positive 
15-64 
% 
Influenza 
Positive 
≥45 
% 
Influenza 
Positive 
≥65 
Total % 
Influenza 
Positive 
Stockholm, 
Sweden27 
2004-2005 general Pneumonia >=18 Polymerase Chain 
Reaction, Viral 
Culture (Respiratory 
Specimen), and 
Enzyme-linked 
Immunosorbent 
Assay (Paired Sera) 
7.6 - - - 7.6 
Schiedam, 
Netherlands28 
1998-1999 general Pneumonia >=18 Complement Fixation 
and 
Immunofluorescence 
(Single or Paired 
Sera) 
21.7 - - - 21.7 
Rome, Italy29 2004-2005 general Pulmonary 
Diseases 
Adults Polymerase Chain 
Reaction 
1.0 - - - 1.0 
Turin, Italy30 2008-2008 general Respiratory 
Infection 
>=18 Polymerase Chain 
Reaction and Viral 
Culture 
0.6 - - - 0.6 
Caen, 
France31 
2003-2004 other Intubation in 
ICU patients 
Adults Polymerase Chain 
Reaction, 
Immunofluorescence 
Assay, and Viral 
Culture 
3.7 - - - 3.7 
St Louis, 
Missouri, 
United 
States32 
2005-2006 general Acute 
Respiratory 
Infection 
Adults Polymerase Chain 
Reaction, 
Immunofluorescence 
Assay, and Viral 
Culture 
2.8 - - - 2.8 
Houston, 
Texas, United 
States33 
1993-1995 general Acute 
Respiratory 
Infection 
>=18 Polymerase Chain 
Reaction, Viral 
Culture (Multiple 
Respiratory 
Specimens), and 
Hemagglutination 
Inhibition Assay 
(Paired Sera) 
 
8.7 9.5 8.5 6.5 8.7 
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Location Years Study 
Population 
Case Definition Age 
Range 
Diagnostic Test % 
Influenza 
Positive 
≥14 
% 
Influenza 
Positive 
15-64 
% 
Influenza 
Positive 
≥45 
% 
Influenza 
Positive 
≥65 
Total % 
Influenza 
Positive 
Edmonton, 
Canada34 
2004-2006 general Pneumonia Adults Polymerase Chain 
Reaction and 
Immunofluorescence 
Assay 
3.6 - - - 3.6 
Singapore, 
Singapore35 
1995-1997 COPD Acute 
Exacerbations of 
COPD 
Adults Complement Fixation 
(Paired Sera) 
24.4 - - - 24.4 
Melbourne, 
Australia36 
2003-2005 COPD Acute 
Exacerbations of 
COPD 
>=65 Polymerase Chain 
Reaction (Multiple 
Respiratory 
Specimens) and 
Complement Fixation 
(Paired Sera) 
- - 2.0 - 2.0 
Multiple Sites, 
Japan37 
1994-1997 general Pneumonia >=18 Complement Fixation 
(Paired or Single 
Serum) 
1.4 - - - 1.4 
Christchurch, 
New 
Zealand38 
1999-2000 general Pneumonia >=18 Polymerase Chain 
Reaction, Viral 
Culture (Respiratory 
Specimen), 
Immunofluorescence 
Assay, and 
Complement Fixation 
(Paired Sera) 
9.5 - - - 9.5 
Multiple Sites, 
Japan39 
1998-2000 general Pneumonia >=65 Viral Culture 
(Respiratory 
Specimen) and 
Complement Fixation 
(Paired Sera) 
- - - 7.1 7.1 
Newcastle, 
Australia40 
2000-2003 other Acute 
Exacerbations of 
COPD 
>=65 Polymerase Chain 
Reaction, 
Immunofluorescence 
Assay (Paired Sera), 
and Viral Culture 
(Multiple Respiratory 
Specimens) 
- - 17.8 - 17.8 
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Location Years Study 
Population 
Case Definition Age 
Range 
Diagnostic Test % 
Influenza 
Positive 
≥14 
% 
Influenza 
Positive 
15-64 
% 
Influenza 
Positive 
≥45 
% 
Influenza 
Positive 
≥65 
Total % 
Influenza 
Positive 
Melbourne, 
Australia41 
1993-1994 other Acute 
Exacerbation of 
Asthma 
>=18 Viral Culture 
(Respiratory 
Specimen) and 
Complement Fixation 
(Paired Sera) 
25.3 - - - 25.3 
Ljubljana, 
Slovenia42 
1996-1997 general Pneumonia >=18 Viral Culture 
(Respiratory 
Specimen) and 
Complement Fixation 
(Paired Sera) 
1.9 - - - 1.9 
* Estimates for Influenza A only
84 
 
References for Published Datasets Used in Analyses 
1. Behbehani N, Mahmood A, Mokaddas EM, et al. Significance of atypical pathogens among community-
acquired pneumonia adult patients admitted to hospital in Kuwait. Medical principles and practice : 
international journal of the Kuwait University, Health Science Centre 2005; 14(4): 235-40. 
2. Ko FW, Ip M, Chan PK, Ng SS, Chau SS, Hui DS. A one-year prospective study of infectious etiology in 
patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Respiratory medicine 
2008; 102(8): 1109-16. 
3. Mermond S, Berlioz-Arthaud A, Estivals M, Baumann F, Levenes H, Martin PM. Aetiology of community-
acquired pneumonia in hospitalized adult patients in New Caledonia. Tropical medicine & international 
health : TM & IH 2010; 15(12): 1517-24. 
4. Scott JA, Hall AJ, Muyodi C, et al. Aetiology, outcome, and risk factors for mortality among adults with 
acute pneumonia in Kenya. Lancet 2000; 355(9211): 1225-30. 
5. Hara K, Yahara K, Gotoh K, et al. Clinical study concerning the relationship between community-acquired 
pneumonia and viral infection in northern Thailand. Internal medicine (Tokyo, Japan) 2011; 50(9): 991-8. 
6. Suttinont C, Losuwanaluk K, Niwatayakul K, et al. Causes of acute, undifferentiated, febrile illness in rural 
Thailand: results of a prospective observational study. Annals of tropical medicine and parasitology 2006; 
100(4): 363-70. 
7. Díaz F A, Fuentes L G, Couble P B, et al. Etiología de la neumonía adquirida en la comunidad en adultos 
hospitalizados en Santiago, Chile: implicancias para las guías clínicas. Revista chilena de enfermedades 
respiratorias 2005; 21: 23-32. 
8. Caberlotto OJ, Cadario ME, Garay JE, Copacastro CA, Cabot A, Savy VL. [Community-acquired 
pneumonia in patients in 2 hospital populations]. Medicina 2003; 63(1): 1-8. 
9. Zhou Y, Lu X, Chen X, Yang L, Liu H, Yu H. Viral etiology of acute lower respiratory infection in adult 
inpatients. [Chinese]. Chinese Journal of Respiratory and Critical Care Medicine 2010; 24(2): 121-4. 
10. Zhang Z, Hu X, Gao X. Clinical study on community- acquired adult respiratory tract infection of influenza 
virus A. ZhongGuo shiyong Neike Zazhi 2003; (2): 80-3. 
11. Zhou Y, Lu X, Chen X. Study on the relationship between respiratory viruses and lower respiratory tract 
infection in adult patients. Chinese Journal of Respiratory and Critical Care Medicine 2010; 9(4): 378-82. 
12. Rabella N, Rodriguez P, Labeaga R, et al. Conventional respiratory viruses recovered from 
immunocompromised patients: clinical considerations. Clinical infectious diseases : an official publication 
of the Infectious Diseases Society of America 1999; 28(5): 1043-8. 
13. Muller A, Klinkenberg D, Vehreschild J, et al. Low prevalence of human metapneumovirus and human 
bocavirus in adult immunocompromised high risk patients suspected to suffer from Pneumocystis 
pneumonia. The Journal of infection 2009; 58(3): 227-31. 
14. Torres A, Dorca J, Zalacain R, et al. Community-acquired pneumonia in chronic obstructive pulmonary 
disease: a Spanish multicenter study. American journal of respiratory and critical care medicine 1996; 
154(5): 1456-61. 
15. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary 
disease requiring hospitalisation: a case-control study. Thorax 2003; 58(1): 37-42. 
16. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. 
Chest 2002; 122(4): 1264-70. 
17. Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial 
pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41(10): 
1438-44. 
18. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-
acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51(2): 179-84. 
19. Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study 
among adults requiring admission to hospital. Thorax 1995; 50(5): 543-7. 
20. Fernandez-Sabe N, Carratala J, Roson B, et al. Community-acquired pneumonia in very elderly patients: 
causative organisms, clinical characteristics, and outcomes. Medicine 2003; 82(3): 159-69. 
21. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in 
adults admitted to hospital: implications for management guidelines. Thorax 2001; 56(4): 296-301. 
22. Jokinen C, Heiskanen L, Juvonen H, et al. Microbial etiology of community-acquired pneumonia in the 
adult population of 4 municipalities in eastern Finland. Clinical infectious diseases : an official publication 
of the Infectious Diseases Society of America 2001; 32(8): 1141-54. 
23. Hohenthal U, Vainionpaa R, Meurman O, et al. Aetiological diagnosis of community acquired pneumonia: 
utility of rapid microbiological methods with respect to disease severity. Scandinavian journal of infectious 
diseases 2008; 40(2): 131-8. 
85 
 
24. Diederen BM, Van Der Eerden MM, Vlaspolder F, Boersma WG, Kluytmans JA, Peeters MF. Detection of 
respiratory viruses and Legionella spp. by real-time polymerase chain reaction in patients with community 
acquired pneumonia. Scandinavian journal of infectious diseases 2009; 41(1): 45-50. 
25. Templeton KE, Scheltinga SA, van den Eeden WC, Graffelman AW, van den Broek PJ, Claas EC. 
Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain 
reaction. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 
2005; 41(3): 345-51. 
26. Angeles Marcos M, Camps M, Pumarola T, et al. The role of viruses in the aetiology of community-
acquired pneumonia in adults. Antiviral therapy 2006; 11(3): 351-9. 
27. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired 
pneumonia: increased microbiological yield with new diagnostic methods. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 2010; 50(2): 202-9. 
28. Braun JJ, de Graaff CS, de Goey J, Zwinderman AH, Petit PL. [Community-acquired pneumonia: pathogens 
and course in patients admitted to a general hospital]. Nederlands tijdschrift voor geneeskunde 2004; 
148(17): 836-40. 
29. Minosse C, Selleri M, Zaniratti MS, et al. Frequency of detection of respiratory viruses in the lower 
respiratory tract of hospitalized adults. Journal of clinical virology : the official publication of the Pan 
American Society for Clinical Virology 2008; 42(2): 215-20. 
30. Gambarino S, Mantovani S, Astegiano S, et al. Lower respiratory tract viral infections in hospitalized adult 
patients. Minerva medica 2009; 100(5): 349-55. 
31. Daubin C, Parienti JJ, Vincent S, et al. Epidemiology and clinical outcome of virus-positive respiratory 
samples in ventilated patients: a prospective cohort study. Critical care (London, England) 2006; 10(5): 
R142. 
32. Sumino KC, Walter MJ, Mikols CL, et al. Detection of respiratory viruses and the associated chemokine 
responses in serious acute respiratory illness. Thorax 2010; 65(7): 639-44. 
33. Atmar RL, Piedra PA, Patel SM, Greenberg SB, Couch RB, Glezen WP. Picornavirus, the most common 
respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness. 
Journal of clinical microbiology 2012; 50(2): 506-8. 
34. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-
acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134(6): 1141-8. 
35. Goh SK, Johan A, Cheong TH, Wang YT. A prospective study of infections with atypical pneumonia 
organisms in acute exacerbations of chronic bronchitis. Annals of the Academy of Medicine, Singapore 
1999; 28(4): 476-80. 
36. Hutchinson AF, Ghimire AK, Thompson MA, et al. A community-based, time-matched, case-control study 
of respiratory viruses and exacerbations of COPD. Respiratory medicine 2007; 101(12): 2472-81. 
37. Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Etiology of community-acquired pneumonia in 
hospitalized patients: a 3-year prospective study in Japan. Chest 1998; 114(6): 1588-93. 
38. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired 
pneumonia in adults. Thorax 2008; 63(1): 42-8. 
39. Kobashi Y, Okimoto N, Matsushima T, Soejima R. Clinical analysis of community-acquired pneumonia in 
the elderly. Internal medicine (Tokyo, Japan) 2001; 40(8): 703-7. 
40. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ. Virus infection in exacerbations of 
chronic obstructive pulmonary disease requiring ventilation. Intensive care medicine 2006; 32(7): 1022-9. 
41. Teichtahl H, Buckmaster N, Pertnikovs E. The incidence of respiratory tract infection in adults requiring 
hospitalization for asthma. Chest 1997; 112(3): 591-6. 
42. Socan M, Marinic-Fiser N, Kraigher A, Kotnik A, Logar M. Microbial aetiology of community-acquired 
pneumonia in hospitalised patients. European journal of clinical microbiology & infectious diseases : 
official publication of the European Society of Clinical Microbiology 1999; 18(11): 777-82. 
 
 
 
 
 
 
 
 
 
 
86 
 
 
Appendix 3. Summary of unpublished (surveillance) datasets 
Country Years 
Number of 
inpatient sites 
Total number 
tested 
Angola 2009 - 2011 2 111 
Bangladesh 2007- 2011 12 3338 
Cambodia 2009 - 2011 3 849 
China(IEIP) 2010 - 2012 1 2178 
China (Sentinel) 2011 - 2012 10 1462 
Costa Rica 2006 - 2009 10 115 
Cote d'Ivoire 2009 - 2011 3 53 
DRC 2009 - 2011 3 359 
El Salvador 2007 - 2011 
 
1754 
Ghana 2009 - 2011 4 695 
Guatemala 2008 - 2011 3 1457 
India (Ballabgarh) 2009 - 2011 33 651 
India (Vadu) 2009 - 2011 38 1538 
Indonesia 2011 11 179 
Kenya 2006 - 2011 9 569 
Kyrgyz 2009 - 2011 4 266 
Lao 2008 - 2011 5 206 
Mexico 2003 - 2010 1 205 
Moldova 2009 - 2011 9 1394 
Mongolia 2006 - 2011 35 3256 
Morocco 2007 - 2011 16 720 
Nigeria 2008 - 2011 4 317 
Paraguay 2010 - 2011 4 1065 
Philippines 2009 - 2011 6 626 
South Africa 2009 - 2011 5 6370 
Tanzania 2008 - 2011 5 205 
Thailand (RPS) 2005 - 2011 20 12779 
Thailand (MOPH) 2010 - 2011 3 218 
Vietnam 2011 - 2012 8 800 
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Appendix 4. Pandemic crude proportion of respiratory samples from hospitalized adults testing positive for 
influenza by age group, study design, and population including all datasets*† 
 No. of 
studies 
(n=) 
Median 
Number (IQR) 
Median Percent Positive (IQR) p-value** 
   Tested Positive  
Age group in years      
≥14 9 501(123, 835) 162(52, 187) 23% (0.13, 0.34) 0.8651 
18 to 64 8 567(229, 856) 113(11, 227) 22% (0.15, 0.30)  
≥45 6 246(159, 332) 43(40, 56) 19% (0.14, 0.25)  
≥65 4 147(110, 444) 23(20, 379) 18% (0.16, 0.60)  
Diagnostic test      
PCR only 3 95(70, 830) 13(9, 162) 14% (0.13, 0.20) 0.1213 
Immunofluorescence 
only 
0 0 0 0%  
Culture only 0 0 0 0%  
Serology Only 0 0 0 0%  
Multiple diagnostic 
tests, incl. PCR 
6 668(447, 1752) 180(103, 316) 29% (0.23, 0.38)  
Multiple diagnostic 
tests, excl. PCR 
0 0 0 0%  
Case definition      
Acute Respiratory 
Infection 
0 0 0 0% 0.0404 
Acute Lower 
Respiratory Infection 
2 911(70, 1752) 98(9, 187) 12% (0.11, 0.13)  
Pneumonia 0 0 0 0%  
Severe Acute 
Respiratory Illness 
21 720(317, 1457) 162(52, 316) 24% (0.20, 0.38)  
Other 0 0 0 0%  
WHO region      
African 1 95 13 14% 0.3330 
Eastern 
Mediterranean 
1 501 172 34%  
European 1 123 52 42%  
Americas 2 641(447, 835) 210(103, 316) 30%(0.23, 0.38)  
Southeast Asian 
2 
1291(830, 
1752) 
175(162, 187) 15%(0.11, 0.20)  
Western Pacific 2 969(70, 1869) 232(9, 454) 19% (0.13, 0.24)  
World Bank Income Level      
Low 4 109(83, 477) 33(11, 107) 17%(0.13, 0.31) 0.6242 
Lower Middle 5 835(501, 1752) 187(172, 316) 24%(0.23, 0.34)  
Upper Middle 0 0 0 0%  
High 0 0 0 0%  
*Six eligible articles provided data for influenza A only, and were excluded from the overall positive analyses 
**Kruskal-Wallis/Wilcoxon rank sum test. 
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. Since data was provided by year in 
the unpublished datasets, three unpublished datasets were included in two timeframes; six unpublished datasets were in all three timeframes.   
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Appendix 5. Assessment of the Impact of Dataset Quality on Positive Proportions 
 
5a. Median Influenza-Positive Proportion for Respiratory Samples from Hospitalized Adults in Published Datasets only shown below by Bias Score 
bias low score medium score high score KW p-value 
  
No. of datasets 
(n=) 
Median Percent 
Positive (IQR) 
No. of datasets 
(n=) 
Median Percent 
Positive (IQR) 
No. of 
datasets 
(n=) 
Median Percent 
Positive (IQR)   
selection  10 6% (0.03, 0.10)     31 8% (0.04, 0.17) 0.8081 
comparability 9 6% (0.02, 0.14)     32 8% (0.05, 0.18) 0.7528 
outcome 14 9% (0.06, 0.13)     27 8% (0.04, 0.18) 0.9124 
total 8 8% (0.02, 0.13) 17 7% (0.05, 0.16) 16 8% (0.04, 0.19) 0.9255 
Total bias = selection bias + comparability bias + outcome bias 
Low score is a score of 1 or 0 for total and a score of 0 for individual bias. 
Medium score is a score of 2 for total; no medium score used for individual bias. 
High score is a score of 3 for total and score of 1 for individual bias. 
 
 
5b. Median Influenza-Positive Proportion Stratified by PCR testing 
    5bi. PCR tested 
       Bias low score medium score high score KW p-value 
  
No. of datasets 
(n=) 
Median Percent 
Positive (IQR) 
No. of datasets 
(n=) 
Median Percent 
Positive (IQR) 
No. of 
datasets 
(n=) 
Median Percent 
Positive (IQR)   
selection  6 5% (0.03, 0.10)     12 13% (0.08, 0.18) 0.0394 
comparability 5 9% (0.04, 0.10)     13 10% (0.07, 0.18) 0.4597 
outcome 3 10% (0.10, 0.13)     15 8% (0.05, 0.18) 0.3743 
Total 4 10% (0.03, 0.13) 6 5% (0.04, 0.09) 8 14% (0.08, 0.21) 0.1866 
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  5bii. No PCR 
       
Bias low score medium score high score 
KW p-
value 
  
No. of datasets 
(n=) 
Median Percent 
Positive (IQR) 
No. of 
datasets 
(n=) 
Median 
Percent 
Positive 
(IQR) 
No. of 
datasets 
(n=) 
Median 
Percent 
Positive (IQR)   
selection  3 20% (0.02, 0.24)     18 6% (0.02, 0.10) 0.3657 
comparability 3 2%(0.01, 0.25)     18 7% (0.02, 0.16) 0.763 
outcome 11 7% (0.01, 0.16)     10 5% (0.02, 0.20) 0.7782 
Total 3 2% (0.01, 0.25) 11 
8% (0.06, 
0.20) 7 4% (0.02, 0.07) 0.5196 
 
 
 
5c. Median Influenza-Positive Proportion Stratified by Timeframe  
    5ci.Seasonal 
       bias low score medium score high score KW p-value 
  
No. of datasets 
(n=) 
Median Percent 
Positive (IQR) 
No. of datasets 
(n=) 
Median Percent 
Positive (IQR) 
No. of 
datasets 
(n=) 
Median Percent 
Positive (IQR)   
selection  10 8% (0.03, 0.11)     32 8% (0.04, 0.17) 0.8081 
comparability 9 9% (0.03, 0.11)     33 8% (0.05, 0.17) 0.7528 
outcome 15 9% (0.06, 0.13)     27 8% (0.04, 0.18) 0.9124 
total 8 10% (0.02, 0.13) 17 7% (0.05, 0.16) 16 8% (0.05, 0.18) 0.9255 
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Appendix 6. Evaluating Impact of pandemic H1N1 in 2010 calendar year 
 
6a. Crude positive proportions for seasonal influenza by 2010 data  
   
 
Datasets without 2010 Data 
   
   
  
No. of studies 
(n=) 
Median Percent 
Positive (IQR) p-value 
  
   
Age group in years   
    
   
≥14 65 8% (0.04, 0.14) 0.902 
  
   
18 to 64 30 11% (0.06, 0.15) 
   
   
≥45 25 8% (0.02, 0.13) 
   
   
≥65 19 11% (0.06, 0.15) 
   
   
Type of study   
    
   
Unpublished surveillance 30 10% (0.04, 0.14) 0.8512 
  
   
Published  39 8% (0.04, 0.17) 
   
   
Diagnostic test   
    
   
Polymerase Chain Reaction (PCR) only 13 11% (0.10, 0.17) 0.094 
  
   
Immunofluorescence only 1 7% 
   
   
Culture only 1 1% 
   
   
Serology Only 10 6% (0.02, 0.16) 
   
   
Multiple diagnostic tests, incl. PCR 39 8% (0.03, 0.11) 
   
   
Multiple diagnostic tests, excl. PCR 5 20% (0.07, 0.22) 
   
   
Case definition   
    
   
Acute Respiratory Infection 4 6% (0.02, 0.11) 0.4646 
  
   
Acute Lower Respiratory Infection 6 12% (0.07, 0.14) 
   
   
Pneumonia 24 7% (0.04, 0.10) 
   
   
Severe Acute Respiratory Illness 24 9% (0.03, 0.12) 
   
   
Other 11 16% (0.04, 0.22) 
   
   
Study population   
    
   
General adult population 58 8% (0.05, 0.13) 0.1549 
  
   
COPD 6 12% (0.02, 0.22) 
   
   
Immunocompromised 2 1% (0.01, 0.02) 
   
   
Other 3 18% (0.04, 0.25) 
   
   
WHO region   
    
   
African 8 8% (0.06, 0.12) 0.9827 
  
   
Eastern Mediterranean 1 10% 
   
   
European 22 8% (0.02, 0.16) 
   
   
Americas 9 7% (0.04, 0.10) 
   
   
Southeast Asian 9 10% (0.06, 0.14) 
   
   
Western Pacific 20 9% (0.03, 0.18) 
   
   
World Bank income level   
    
   
Low 10 10% (0.06, 0.14) 0.436 
  
   
Lower Middle 19 6% (0.03, 0.14) 
   
   
Upper Middle 8 12% (0.08, 0.19) 
   
   
High 32 8% (0.03, 0.14) 
   
   
Development Status   
    
   
Developing 39 10% (0.06, 0.14) 0.2261 
  
   
Industrialized 30 7% (0.02, 0.13)   
  
   
*Thirteen eligible articles provided data for influenza A only, and were excluded from the overall positive analyses 
   
**Kruskal-Wallis/Wilcoxon rank sum test.  
   †Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. 
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6b. Pooled estimates for seasonal influenza without 2010  
 
  
 
Datasets without 2010 Data 
  
PCR 
Tested 
N* 
PCR tested 
Pooled % 
Positive (95% CI) N† 
Pooled % 
Positive (95% 
CI)† 
Age group in years   
   ≥14 42 10% (0.08, 0.13) 66 9% (0.08, 0.11) 
18 to 64 26 11% (0.07, 0.17) 30 11% (0.07, 0.17) 
≥45 19 9% (0.09, 0.10) 25 9% (0.09, 0.09) 
≥65 13 did not converge 19 did not converge 
Study population   
   General adult popn 39 10% (0.08, 0.13) 58 10% (0.08, 0.12) 
Special population** 5 9% (0.03, 0.30) 9 12% (0.07, 0.22) 
WHO region     
  African 7 9% (0.07, 0.12) 8 9% (0.07, 0.11) 
Americas 2 6% (0.0001, 47) 9 8% (0.05, 0.12) 
Eastern Mediterranean 0 0% 1 
 European 10 16% (0.07, 0.38) 22 10% (0.05, 0.18) 
Southeast Asian 9 did not converge 9 did not converge 
Western Pacific 16 10% (0.08, 0.13) 20 10% (0.08, 0.13) 
Income level   
   Low Income 9 8% (0.04, 0.14) 10 8% (0.05, 0.13) 
Lower Middle Income 15 11% (0.04, 0.32) 19 11% (0.05, 0.25) 
Upper Middle Income 5 10% (0.07, 0.15) 8 10% (0.08, 0.14) 
High Income 15 9% (0.06, 0.12) 32 8% (0.06, 0.11) 
Development status†     
  Developing 31 10% (0.07, 0.15) 39 10% (0.08, 0.13) 
Industrialized 13 8% (0.06, 0.12) 30 7% (0.5, 0.10) 
*Number of data points included in model, including multiple individual years from a single dataset, when available 
**Includes ICU patients, acute asthma patients, COPD patients, and immunocompromised patients 
†All diagnostic tests included 
‡no PCR data 
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients 
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Appendix 7. Evaluating Impact of Partial-year Influenza Testing  
7a. Seasonal crude positive proportions for datasets stratified by partial-years  
   
 
Datasets with partial-years  
 
Datasets with full-years 
 
  
No. of 
studies 
(n=) 
Median Percent 
Positive (IQR) 
p-
value 
No. of studies 
(n=) 
Median Percent 
Positive (IQR) 
p-
value 
Age group in years 
   
  
  ≥14 20 9% (0.06, 0.12) 0.4649 43 9% (0.04, 0.22) 0.4765 
18 to 64 7 10% (0.06, 0.21) 
 
12 10% (0.04, 0.15) 
 ≥45 7 11% (0.09, 0.19) 
 
19 9% (0.04, 0.14) 
 ≥65 5 10% (0.06, 0.11) 
 
26 10% (0.07, 0.15) 
 Type of study 
   
  
  Unpublished surveillance 5 10% (0.08, 0.21) 0.3676 20 11% (0.06, 0.15) 0.2709 
Published  17 10% (0.06, 0.13) 
 
22 7% (0.02, 0.20) 
 Timeframe for outcome data 
   
  
  Pre-2009† 18 10% (0.6, 0.14) 0.2571 29 8% (0.02, 0.17) 0.038 
Post-2009 6 13% (0.08, 0.18) 
 
20 12% (0.08, 0.20) 
 Diagnostic test 
   
  
  Polymerase Chain Reaction (PCR) 
only 6 19% (0.10, 0.22) 0.1751 16 11% (0.07, 0.15) 0.3086 
Immunofluorescence only 1 7% 
 
0 0% 
 Culture only 0 0% 
 
1 1% 
 Serology Only 5 6% (0.6, 0.10) 
 
5 6% (0.02, 0.21) 
 Multiple diagnostic tests, incl. 
PCR 10 9% (0.08, 0.10) 
 
42 8% (0.03, 0.14) 
 Multiple diagnostic tests, excl. 
PCR 0 0% 
 
5 20% (0.07, 0.22) 
 Case definition 
   
  
  Acute Respiratory Infection 2 6% (0.03, 0.09) 0.032 3 13% (0.01, 0.17) 0.9681 
Acute Lower Respiratory Infection 2 17% (0.13, 0.21) 
 
6 12% (0.07, 0.14) 
 Pneumonia 9 7% (0.06, 0.10) 
 
15 7% (0.02, 0.20) 
 Severe Acute Respiratory Illness 2 9% (0.08, 0.10) 
 
39 10% (0.05, 0.15) 
 Other 7 17% (0.16, 0.22) 
 
6 6% (0.02, 0.24) 
 Study population 
   
  
  General adult population 18 9% (0.06, 0.10) 0.4309 35 10% (0.05, 0.15) 0.2257 
COPD 3 16% (0, 0.22) 
 
3 8% (0.02, 0.24) 
 Immunocompromised 0 0% 
 
2 1% (0.01, 0.02) 
 Other 1 18% 
 
2 15% (0.04, 0.25) 
 WHO region 
   
  
  African 1 6% 0.4022 14 9% (0.06, 0.14) 0.7672 
Eastern Mediterranean 1 10% 
 
0 0% 
 European 8 10% (0.07, 0.14) 
 
16 7% (0.02, 0.17) 
 Americas 5 7% (0.04, 0.09) 
 
7 12% (0.06, 0.18) 
 Southeast Asian 2 14% (0.04, 0.23) 
 
12 12% (0.07, 0.16) 
 Western Pacific 5 17% (0.10, 0.18) 
 
21 9% (0.03, 0.17) 
 World Bank income level 
   
  
  Low 2 13% (0.06, 0.21) 0.9284 8 10% (0.07, 0.14) 0.4374 
Lower Middle 3 10% (0.04, 0.23) 
 
11 11% (0.04, 0.15) 
 Upper Middle 3 8% (0.07, 0.17) 
 
5 13% (0.08, 0.20) 
 High 14 10% (0.06, 0.13) 
 
18 6% (0.02, 0.19) 
 Development Status 
   
  
  Developing 9 10% (0.07, 0.17) 0.4425 25 11% (0.06, 0.15) 0.0464 
Industrialized 13 10% (0.06, 0.13)   17 5% (0.02, 0.08)   
*Thirteen eligible articles provided data for influenza A only, and were excluded from the overall positive analyses 
**Kruskal-Wallis/Wilcoxon rank sum test.  
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. 
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7b. Influenza-positive pooled estimates for datasets stratified by partial-years  
    
 
Datasets with partial-years  Datasets with full-years 
  
PCR 
Tested 
N* 
PCR tested 
Pooled % 
Positive (95% 
CI) N† 
Pooled % Positive 
(95% CI)† PCR Tested N* 
PCR tested Pooled % 
Positive (95% CI) N† 
Pooled % Positive 
(95% CI)† 
Age group in years 
    
  
   ≥14 14 12% (0.08, 0.16) 20 11% (0.08, 0.14) 48 11%(0.09, 0.14) 68 11% (0.09, 0.13) 
18 to 64 7 13% (0.07, 0.24) 7 13% (0.07, 0.24) 37 12% (0.09, 0.16) 43 12% (0.09, 0.16) 
≥45 6 11% (0.08, 0.15) 7 11% (0.08, 0.15) 27 10% (0.09, 0.11) 34 10% (0.09, 0.11) 
≥65 5 11% (0.08, 0.14) 5 11% (0.08, 0.14) 18 10% 26 10% 
Study population 
    
  
   General adult population 13 11% (0.08, 0.16) 18 11% (0.08, 0.14) 46 11% (0.09, 0.14) 62 11% (0.09, 0.13) 
Special population** 2 20% (0.05, 0.86) 4 14% (0.05, 0.37) 3 4% (0.008, 0.17) 5 10% (0.03, 0.39) 
WHO region     
  
    
  African 
  
1 
 
14 9% (0.07, 0.12) 14 9% (0.07, 0.12) 
Americas 3 9% (0.03, 0.23) 5 8% (0.05, 0.14)   
 
7 14% (0.07, 0.30) 
Eastern Mediterranean 
  
1 
 
  
   European 5 11% (0.07, 0.18) 8 10% (0.07, 0.16) 7 21% (0.06, 0.68) 16 10% (0.04, 0.23) 
Southeast Asian 2 
17% (0.0002, 
143) 2 17% (0.0002, 143) 12 11% (0.08, 0.16) 12 11% (0.08, 0.16) 
Western Pacific 5 10% (0.06, 0.18) 5 10% (0.06, 0.18) 16 11% (0.08, 0.16) 20 11% (0.08, 0.15) 
Income level 
    
  
   Low Income 1 
 
2 12% (0.00005, 254) 16 13% (0.10, 0.17) 16 13% (0.10, 0.17) 
Lower Middle Income 3 14% (0.03, 0.72) 3 14% (0.03, 0.72) 22 12% (0.07, 0.19) 28 12% (0.08, 0.17) 
Upper Middle Income 2 9% (0.002, 5.6) 3 9% (0.03, 0.24) 5 10% (0.04, 0.26) 7 10% (0.06, 0.17) 
High Income 9 10% (0.07, 0.14) 14 9% (0.07, 0.12) 6 7% (0.03, 0.17) 18 7% (0.04, 0.12) 
Development status†     
  
    
  Developing 6 13% (0.07, 0.24) 9 12% (0.08, 0.19) 45 11% (0.09, 0.14) 52 11% (0.09, 0.14) 
Industrialized 9 10% (0.07, 0.14) 13 9% (0.06, 0.13) 4 5% (0.02, 0.10) 17 6% (0.3, 0.11) 
*Number of data points included in model, including multiple individual years from a single dataset, when available 
**Includes ICU patients, acute asthma patients, COPD patients, and immunocompromised patients 
†All diagnostic tests included  
‡no PCR data 
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients 
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients 
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Appendix 8. Evaluating Impact of Multipathogen Detection 
 
8a. Crude positive proportions   
     
 
Studies with Multipathogen detection 
  
  
No. of studies 
(n=) 
Median Percent 
Positive (IQR) p-value 
  Age group in years 
     ≥14 37 8% (0.04, 0.15) 0.4386 
  18 to 64 2 14%(0.09, 0.18) 
   ≥45 6 8% (0.02, 0.18) 
   ≥65 5 7% (0.06, 0.16) 
   Type of study 
     Unpublished surveillance 0 0% 
   Published  41 8% (0.04, 0.17) 
   Timeframe for outcome data 
     Pre-2009† 41 8% (0.04, 0.17) 
   During 2009 ("pandemic") 0 0% 
   Post-2009 0 0% 
   Diagnostic test 
     Polymerase Chain Reaction (PCR) 
only 5 17% (0.10, 0.22) 0.1922 
  Immunofluorescence only 1 7% 
   Culture only 1 1% 
   Serology Only 10 6% (0.02, 0.16) 
   Multiple diagnostic tests, incl. PCR 17 8% (0.04, 0.10) 
   Multiple diagnostic tests, excl. PCR 5 20% (0.07, 0.22) 
   Case definition 
     Acute Respiratory Infection 3 3% (0.01, 0.09) 0.2715 
  Acute Lower Respiratory Infection 1 13% 
   Pneumonia 24 7% (0.04, 0.10) 
   Severe Acute Respiratory Illness 0 0% 
   Other 11 16% (0.04, 0.22) 
   Study population 
     General adult population 28 8% (0.05, 0.12) 0.1751 
  COPD 6 12% (0.02, 0.22) 
   Immunocompromised 2 1% (0.01, 0.02) 
   Other 3 18% (0.04, 0.25) 
   WHO region 
     African 1 6% 0.5452 
  Eastern Mediterranean 1 10% 
   European 20 7% (0.02, 0.12) 
   Americas 5 7% (0.04, 0.09) 
   Southeast Asian 1 6% 
   Western Pacific 11 17% (0.07, 0.23) 
   World Bank income level 
     Low 1 6% 0.7587 
  Lower Middle 1 6% 
   Upper Middle 5 17% (0.07, 0.20) 
   High 32 8% (0.03, 0.14) 
   Development Status 
     Developing 10 10% (0.07, 0.19) 0.1252 
  Industrialized 30 7% (0.02, 0.13)   
  *Thirteen eligible articles provided data for influenza A only, and were excluded from the overall positive analyses 
**Kruskal-Wallis/Wilcoxon rank sum test.  
†Pandemic defined as calendar year 2009. Nine studies only provided combined pre-pandemic/pandemic estimates. 
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8b.Pooled estimates   
    
 
Studies with Multipathogen detection 
 
  
PCR 
Tested 
N* 
PCR tested 
Pooled % 
Positive (95% 
CI) N† 
Pooled % Positive 
(95% CI)† 
Age group in years 
    ≥14 16 10% (0.07, 0.13) 36 8% (0.06, 0.11) 
18 to 64 2 13% (0.002, 8.3) 2 13% (0.002, 8.3) 
≥45 4 11% (0.03, 0.34) 6 9% (0.04, 0.22) 
≥65 2 12% (0.001, 19) 5 10% (0.04, 0.28) 
Study population       
 General adult population 13 10% (0.07, 0.13) 28 8% (0.06, 0.11) 
Special population** 5 9% (0.3, 0.30) 11 7% (0.03, 0.16) 
WHO region     
  African 0 0% 1 
 Americas 2 6% (0.0001, 47) 5 7% (0.02, 0.18) 
Eastern Mediterranean 0 0% 1 
 European 8 9% (0.06, 0.13) 20 7% (0.05, 0.11) 
Southeast Asian 1 
 
2 
 Western Pacific 7 13% (0.08, 0.21) 11 12% (0.07, 0.19) 
Income level 
    Low Income 0 0% 1 
 Lower Middle Income 0 0% 2 
 Upper Middle Income 2 19% (0.03, 1.0) 5 12% (0.05, 0.30) 
High Income 15 9% (0.06, 0.12) 32 8% (0.06, 0.11) 
Development status     
  Developing 5 15% (0.09, 0.26) 10 12% (0.09, 0.19) 
Industrialized 13 8% (0.06, 0.12) 30 7% (0.05, 0.10) 
*Number of data points included in model, including multiple individual years from a single dataset, when available 
**Includes ICU patients, acute asthma patients, COPD patients, and immunocompromised patients 
†All diagnostic tests included  
‡no PCR data 
§Includes: ICU patients only, acute asthma patients, immunocompromised patients, and COPD patients 
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Appendix 9. Glossary 
Terms or abbreviation followed by definition 
 
Surface antigens of influenza virus type A 
 HA – hemagglutinin 
 NA – neuraminidase 
 
Public Health Agencies 
 WHO – World Health Organization 
 CDC – Centers for Disease Control and Prevention 
 
Study Timeframe 
 Pre-pandemic – conducting study, collection and testing specimens prior to the 2009-calendar year 
 Pandemic – collecting and testing specimens during the 2009-calendar year 
 Post-pandemic – conducting study, collecting and testing specimens in 2010-calendar year and 
later 
 
Diagnostic Test 
 PCR – Polymerase Chain Reaction 
 Multiple diagnostic tests incl. PCR – study using more than one tests including polymerase chain 
reaction to detect and confirm influenza 
 Multiple diagnostic tests excl. PCR – study using more than one tests excluding polymerase chain 
reaction to detect and confirm influenza 
 Immunofluorescence – a microscopy technique used to detect the presence of a protein 
specifically targeted by fluorescent-labeled antibodies 
 Complement Fixation – immunological assay which includes serum complement for the binding 
of antigen-antibody complexes 
 
Case Definitions 
 SARI – Severe acute respiratory infection 
 ILI – Influenza-like illness 
 ARI – Acute respiratory illness 
 ARLI – Acute respiratory like illness 
 LRTI – Lower respiratory tract illness 
 CAP – Community acquired pneumonia 
 Other – includes acute febrile illness, respiratory infection, acute exacerbation of chronic illness 
 
Study Populations 
 COPD – Chronic obstructive pulmonary disease 
 ICU – Intensive care unit 
 Other – includes ICU patients (only), acute exacerbation of chronic illness 
 Popn – population  
 
Regional Groupings 
 WHO region – six regions that WHO member states are grouped into 
 World Bank income level – 
http://siteresources.worldbank.org/DATASTATISTICS/Resources/OGHIST.xls  
 Development status – United Nations Population Division (UNPD), 2012 World Population 
Prospects Report   
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Statistical Terms 
 CI – confidence intervals 
 IQR – interquartile range; statistic dispersion 
 
Exploratory Analysis 
 Partial-year data - datasets which completed ongoing influenza testing beyond a 12-month period, 
such as 15 and 26 months 
 Multipathogen detection – datasets which tested for other pathogens in addition to influenza type 
A and B 
o RSV – Respiratory syncytial virus 
o M.pna – Mycoplasma pneumoniae  
 
Vaccines and immune status 
 LAIV – Live Attenuated Influenza Vaccine 
 HIV – human immunodeficiency virus 
 Immunosenescence – decreased immune functionality observed or associated with aging   
 
